Single insertion delivery system for treating embolism and associated systems and methods

Information

  • Patent Grant
  • 11849963
  • Patent Number
    11,849,963
  • Date Filed
    Thursday, July 14, 2022
    a year ago
  • Date Issued
    Tuesday, December 26, 2023
    4 months ago
Abstract
Systems and methods for the intravascular treatment of clot material within a blood vessel of a human patient are disclosed herein. A method in accordance with embodiments of the present technology can include, for example, engaging an interventional device of a catheter system with clot material in a blood vessel and withdrawing the interventional device and the portion of the clot material through a guide catheter. In some embodiments, the catheter system can include an attachment/valve member coupled to a proximal portion of the guide catheter, and the method can include unsealing the attachment/valve member to facilitate withdrawing the interventional device through the attachment/valve member without significant retention of clot material within the attachment/valve member. The method can further include resealing and aspirating the guide catheter before advancing another interventional device to the clot material to again engage and remove clot material from the blood vessel.
Description
TECHNICAL FIELD

The present technology relates generally to devices and methods for the intravascular treatment of emboli and/or thrombi within a blood vessel of a human patient. In particular, some embodiments of the present technology relate to systems for repeatedly deploying an interventional device at or proximate to a pulmonary embolism within a patient.


BACKGROUND

Thromboembolic events are characterized by an occlusion of a blood vessel. Thromboembolic disorders, such as stroke, pulmonary embolism, heart attack, peripheral thrombosis, atherosclerosis, and the like, affect many people. These disorders are a major cause of morbidity and mortality.


When an artery is occluded by a clot, tissue ischemia develops. The ischemia will progress to tissue infarction if the occlusion persists. Infarction does not develop or is greatly limited if the flow of blood is reestablished rapidly. Failure to reestablish blood flow can lead to the loss of limb, angina pectoris, myocardial infarction, stroke, or even death.


In the venous circulation, occlusive material can also cause serious harm. Blood clots can develop in the large veins of the legs and pelvis, a common condition known as deep venous thrombosis (DVT). DVT arises most commonly when there is a propensity for stagnated blood (e.g., long distance air travel, immobility, etc.) and clotting (e.g., cancer, recent surgery, such as orthopedic surgery, etc.). DVT causes harm by: (1) obstructing drainage of venous blood from the legs leading to swelling, ulcers, pain, and infection, and (2) serving as a reservoir for blood clots to travel to other parts of the body including the heart, lungs, brain (stroke), abdominal organs, and/or extremities.


In the pulmonary circulation, the undesirable material can cause harm by obstructing pulmonary arteries—a condition known as pulmonary embolism. If the obstruction is upstream, in the main or large branch pulmonary arteries, it can severely compromise total blood flow within the lungs, and therefore the entire body, and result in low blood pressure and shock. If the obstruction is downstream, in large to medium pulmonary artery branches, it can prevent a significant portion of the lung from participating in the exchange of gases to the blood resulting in low blood oxygen and buildup of blood carbon dioxide.


There are many existing techniques to reestablish blood flow through an occluded vessel. One common surgical technique, an embolectomy, involves incising a blood vessel and introducing a balloon-tipped device (such as the Fogarty catheter) to the location of the occlusion. The balloon is then inflated at a point beyond the clot and used to translate the obstructing material back to the point of incision. The obstructing material is then removed by the surgeon. Although such surgical techniques have been useful, exposing a patient to surgery may be traumatic and best avoided when possible. Additionally, the use of a Fogarty catheter may be problematic due to the possible risk of damaging the interior lining of the vessel as the catheter is being withdrawn.


Percutaneous methods are also utilized for reestablishing blood flow. A common percutaneous technique is referred to as balloon angioplasty where a balloon-tipped catheter is introduced to a blood vessel (e.g., typically through an introducing catheter). The balloon-tipped catheter is then advanced to the point of the occlusion and inflated to dilate the stenosis. Balloon angioplasty is appropriate for treating vessel stenosis, but it is generally not effective for treating acute thromboembolisms as none of the occlusive material is removed and the vessel will re-stenos after dilation. Another percutaneous technique involves placing a catheter near the clot and infusing streptokinase, urokinase, or other thrombolytic agents to dissolve the clot. Unfortunately, thrombolysis typically takes hours to days to be successful. Additionally, thrombolytic agents can cause hemorrhage and in many patients the agents cannot be used at all.


Various devices exist for performing a thrombectomy or removing other foreign material. However, such devices have been found to have structures which are either highly complex, cause trauma to the treatment vessel, or lack sufficient retaining structure and thus cannot be appropriately fixed against the vessel to perform adequately. Furthermore, many of the devices have highly complex structures that lead to manufacturing and quality control difficulties as well as delivery issues when passing through tortuous or small diameter catheters. Less complex devices may allow the user to pull through the clot, particularly with inexperienced users, and such devices may not completely capture and/or collect all of the clot material.


Moreover, with many devices, it is difficult or not possible to make repeated attempts at removing clot material (e.g., to make multiple passes with a device). In particular, if a first pass with a device does not completely capture and/or collect all of the clot material, the device and an accompanying catheter system must be removed from the patient, cleaned, and subsequently reinserted into the patient in order to make a second pass and remove additional material. This can be time consuming and traumatic for the patient.


Thus, there exists a need for an improved embolic extraction device.





BRIEF DESCRIPTION OF THE DRAWINGS

Many aspects of the present technology can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on illustrating clearly the principles of the present disclosure.



FIGS. 1A and 1B are perspective views of a retraction and aspiration system shown in a first state and a second state, respectively, in accordance with embodiments of the present technology.



FIGS. 2A-2G are schematic illustrations of a distal portion of the retraction and aspiration system during a clot removal procedure in accordance with embodiments of the present technology.



FIGS. 3A-3C are a fully-exploded view, an isometric view, and a partially-exploded view of a clot reservoir of the retraction and aspiration system in accordance with embodiments of the present technology.



FIG. 4 is a side view of an attachment member and a fluid control unit of the retraction and aspiration system in accordance with embodiments of the present technology.



FIG. 5 is a side cross-sectional view of the attachment member shown in FIG. 4.



FIG. 6 is an isometric view of a first valve insert in accordance with embodiments of the present technology.



FIGS. 7A and 7B are a side view and a side cross-sectional view, respectively, of the first valve insert shown in FIG. 6 inserted into the attachment member shown in FIG. 4 in accordance with embodiments of the present technology.



FIG. 8 is a side view of a second valve insert in accordance with embodiments of the present technology.



FIG. 9 is a side view of the second valve insert shown in FIG. 8 inserted into the attachment member shown in FIG. 4 in accordance with embodiments of the present technology.



FIG. 10 is a flow diagram of a process or method for operating the retraction and aspiration system in accordance with embodiments of the present technology.



FIG. 11 is a side view of an attachment member and a fluid control unit of the retraction and aspiration system in accordance with embodiments of the present technology.



FIG. 12 is a side view of the fluid control unit shown in FIG. 11 in accordance with embodiments of the present technology.



FIGS. 13A and 13B are side cross-sectional views of the attachment member shown in FIG. 11 in a first configuration and a second configuration, respectively, in accordance with embodiments of the present technology.



FIG. 14 is a flow diagram of a process or method for operating the retraction and aspiration system in accordance with embodiments of the present technology.





DETAILED DESCRIPTION

The present technology is generally directed to systems and associated devices and methods for engaging and removing clot material from a blood vessel of a human patient. In some embodiments, an interventional device can be advanced through a guide catheter and deployed within clot material in a blood vessel. The interventional device can subsequently be withdrawn from the patient through the guide catheter to remove clot material captured by the interventional device. In some embodiments of the present technology, the interventional device can be repeatedly deployed in/withdrawn from the blood vessel to capture a desired amount of the clot material—without requiring that the guide catheter be fully withdrawn from the patient after each “pass” (e.g., each repeated deployment/withdrawal of the interventional device). That is, the guide catheter may be inserted only a single time during an intravascular procedure including multiple passes to remove clot material from the patient.


Although many of the embodiments are described below with respect to devices, systems, and methods for treating a pulmonary embolism, other applications and other embodiments in addition to those described herein are within the scope of the technology (e.g., intravascular procedures other than the treatment of emboli, intravascular procedures for treating cerebral embolism, etc.). Additionally, several other embodiments of the technology can have different configurations, states, components, or procedures than those described herein. Moreover, it will be appreciated that specific elements, substructures, advantages, uses, and/or other features of the embodiments described with reference to FIGS. 1A-14 can be suitably interchanged, substituted or otherwise configured with one another in accordance with additional embodiments of the present technology. Furthermore, suitable elements of the embodiments described with reference to FIGS. 1A-14 can be used as standalone and/or self-contained devices. A person of ordinary skill in the art, therefore, will accordingly understand that the technology can have other embodiments with additional elements, or the technology can have other embodiments without several of the features shown and described below with reference to FIGS. 1A-14.


With regard to the terms “distal” and “proximal” within this description, unless otherwise specified, the terms can reference a relative position of the portions of a retraction and aspiration apparatus and/or an associated catheter system with reference to an operator and/or a location in the vasculature. Also, as used herein, the designations “rearward,” “forward,” “upward,” “downward,” etc. are not meant to limit the referenced component to use in a specific orientation. It will be appreciated that such designations refer to the orientation of the referenced component as illustrated in the Figures; the retraction and aspiration system of the present technology can be used in any orientation suitable to the user.


I. SELECTED EMBODIMENTS OF RETRACTION/ASPIRATION SYSTEMS AND METHODS OF USE


FIGS. 1A and 1B are perspective views of a proximal portion of a clot retrieval system 1 configured in accordance with embodiments of the present technology, shown in a first state and a second state, respectively. Referring to FIGS. 1A and 1B together, the clot retrieval system 1 includes a retraction and aspiration device 100 (“RA device 100”), a catheter system 200, and a tubing system 300. In some embodiments, the RA device 100 is coupleable to the catheter system 200 and operable to simultaneously (i) retract a portion of the catheter system 200 and (ii) aspirate through the catheter system 200. In certain embodiments, the RA device 100 and catheter system 200 can both be fluidly coupled to the tubing system 300 to enable material (e.g., blood and clot material) aspirated from the catheter system 200 to flow into the tubing system 300. In particular, the RA device 100, the catheter system 200, and the tubing system 300 can be the same as or similar to one or more of the retraction and aspiration devices, catheter systems, and tubing systems disclosed in U.S. Pat. No. 9,526,864, filed Jun. 9, 2015, and titled “RETRACTION AND ASPIRATION DEVICE FOR TREATING EMBOLISM AND ASSOCIATED METHODS,” which is incorporated herein by reference in its entirety.



FIGS. 2A-2G are schematic illustrations of a distal portion of the clot retrieval system 1 during a clot removal procedure in accordance with embodiments of the present technology. In particular, FIGS. 2A-2G illustrate a distal portion of the catheter system 200 that is positioned proximate to an embolism or clot material within a blood vessel (e.g., a pulmonary blood vessel). Accordingly, operation of the catheter system 200 is described with references to FIGS. 2A-2G.



FIG. 2A is a side view of a distal portion of the catheter system 200 positioned adjacent an embolism or clot material PE within a blood vessel BV (e.g., a pulmonary blood vessel). As shown in FIG. 2A, the catheter system 200 can include an outer guide catheter 206 defining a lumen 205, a delivery sheath 204 slidably received within the lumen of the guide catheter 206, and an elongated pull (and/or push) member 202 slidably received within a lumen of the delivery sheath 204. The guide catheter 206 and the delivery sheath 204 individually comprise an elongated shaft having a lumen and, in some embodiments, the push member 202 can also define a lumen (e.g., configured to receive a guidewire therethrough). In a particular embodiment, the catheter system 200 does not include a guide catheter 206 and/or a delivery sheath 204. As shown in FIG. 2A, a distal portion of the push member 202 can be integral with or coupled to an interventional device ID, such as a clot removal and/or clot treatment device, that is housed within the delivery sheath 204. Accordingly, axial movement of the pull member 202 causes axial movement of the interventional device ID.


As further shown in FIG. 2A, the delivery sheath 204 and the interventional device ID can be positioned at least partially within the clot material PE. Access to the pulmonary vessels can be achieved through the patient's vasculature, for example, via the femoral vein. The catheter system 200 can include an introducer 210 (FIGS. 1A and 1B; e.g., a Y-connector with a hemostasis valve) that can be partially inserted into the femoral vein. A guidewire (not shown) can be guided into the femoral vein through the introducer 210 and navigated through the right atrium, the tricuspid valve, the right ventricle, the pulmonary valve and into the main pulmonary artery. Depending on the location of the embolism, the guidewire can be guided to one or more of the branches of the right pulmonary artery and/or the left pulmonary artery. It will be understood, however, that other access locations into the venous circulatory system of a patient are possible and consistent with the present technology. For example, the user can gain access through the jugular vein, the subclavian vein, the brachial vein or any other vein that connects or eventually leads to the superior vena cava. Use of other vessels that are closer to the right atrium of the patient's heart can also be advantageous as it reduces the length of the instruments needed to reach the pulmonary embolism.


As shown in FIGS. 2B and 2C, the delivery sheath 204 can be withdrawn proximally (e.g., as indicated by arrow A1 in FIG. 2B) to allow the interventional device ID to expand within the clot material PE, thereby grabbing the clot material PE that is nearby. Although FIG. 2B shows the interventional device ID positioned at the treatment site such that a distal terminus of the interventional device ID is distal of a distal terminus of the clot material PE, in some procedures the interventional device ID may be positioned such that the distal terminus of the interventional device ID is proximal of the distal terminus of the clot material PE. As shown in FIG. 2D, in some embodiments the guide catheter 206 can optionally be advanced distally (e.g., as indicated by arrow A2) until the guide catheter 206 is positioned proximate to a proximal portion of the clot material PE.


Referring again to FIGS. 1A and 1B, the RA device 100 includes (i) a housing 102, (ii) an actuation mechanism that includes a lever 104 coupled to and extending from the housing 102, and (iii) a pressure source (obscured in FIGS. 1A and 1B; e.g., a syringe) positioned within the housing 102, coupled to the actuation mechanism, and configured to generate negative and/or positive pressure. The lever 104 is shown in a first position and second position in FIGS. 1A and 1B, respectively. The housing 102 can have a proximal portion 100a, a distal portion 100b, and an opening 114 at the distal portion 100b configured to receive a portion of the catheter system 200 and to mechanically couple the catheter system 200 to the housing 102. For example, a proximal portion of the guide catheter 206 can include an attachment/valve member 208 that is configured to be detachably coupled to the RA device 100 (e.g., via a snap-fit arrangement) to secure the catheter 200 to the RA device 100. As described in greater detail below, the attachment/valve member 208 can fluidly couple an aspiration lumen of the catheter system 200 (e.g., the lumen 205 of the guide catheter 206) to the tubing system 300 of the clot retrieval system 1.


The housing 102 can further include a channel 116 that extends proximally from the opening 114 along approximately the length of the housing 102, as shown in FIGS. 1A and 1B. The channel 116 can have a height at least as great as the outer diameter of the delivery sheath 204 of the catheter system 200 (and/or another component of the catheter system 200) such that the delivery sheath 204 can fit sideways through the channel 116. In some embodiments, the pull member 202 and the interventional device ID (FIGS. 2A-2G) can be pre-loaded into the delivery sheath 204, and the delivery sheath 204 can be fed distally through the channel 116 (e.g., either via the proximal end of the channel 116 or first pushed sideways through a portion of the channel 116) and into the guide catheter 206. In other embodiments, the interventional device ID and the delivery sheath 204 are fed into the guide catheter 206 and the interventional device ID is deployed prior to coupling the guide catheter 206 to the RA device 100.


When the RA device 100 is coupled to the catheter system 200 (e.g., when the attachment/valve member 208 of the catheter system 200 is positioned within the opening 114 in the housing 102 of the RA device 100), movement of the lever 104 functions to retract a portion of the catheter system 200 positioned in the channel 116 (e.g., the delivery sheath 204 and/or the push member 202). For example, the RA device 100 can include a locking portion that grips the delivery sheath 204 (and, in some embodiments, indirectly the push member 202) to pull the delivery sheath 204 proximally as the lever 104 is moved from the first to the second position.


The tubing system 300 of the clot retrieval system 1 fluidly couples the pressure source of the RA device 100 to the aspiration lumen of the catheter system 200. When the RA device 100 is coupled to the catheter system 200, movement of the lever 104 functions to simultaneously generate negative pressure in the pressure source and to retract a portion of the catheter system 200, as described above. The tubing system 300 has a first portion 314 coupled to the pressure source, a second portion 316 coupled to the guide catheter 206, and a drainage portion 318 coupled to a reservoir 320 (e.g., a vinyl bag). The first portion 314, second portion 316, and/or drainage portion 318 can include one or more tubing sections 302 (labeled individually as tubing sections 302a-302f) and/or fluid control unit, such as one or more control valves. In certain embodiments, one or more of the tubing sections 302 can have a relatively large diameter (e.g., greater than about 0.1 inch, greater than about 0.210 inch, etc.) to help inhibit clogging of clot material within the tubing system 300.


More specifically, the first portion 314 can include the tubing section 302a. The drainage portion 318 can include (i) the tubing section 302b, (ii) a first fluid control unit (e.g., a valve) 304, and (iii) the tubing section 302c. The second portion 316 can include (i) the tubing section 302d, (ii) a clot reservoir 306, (iii) the tubing section 302e, (iv) a second fluid control unit 310, and (v) the tubing section 302f. In some embodiments, the first fluid control unit 304 can be a one-way valve (e.g., a check valve) that only allows fluid flow from the first portion 314 and/or second portion 316 to the drainage portion 318 (and not vice-versa). In certain embodiments, as described in detail with reference to FIGS. 3A-3C, the clot reservoir 306 can also include a one-way valve that only allows fluid flow from the second portion 316 to the drainage portion 318 (and not vice-versa). In some embodiments, the second fluid control unit 310 can be a stopcock or a clamp that is externally operated to regulate the flow of liquid through the second portion 316 of the tubing system 300. A Y-connector 308 can fluidly couple the first, second, and drainage portions 314, 316, 318. In other embodiments, the first, second, and/or drainage portions 314, 316, 318 can have more or fewer tubing sections, connectors, and/or fluid control unit and/or other suitable configurations.


As shown in FIGS. 1A and 2E, moving the lever 104 from the first position to the second position (indicated by arrow A1 in FIG. 1A) simultaneously (1) generates a negative pressure in the lumen 205 of the guide catheter 206 (indicated by arrow F in FIG. 1A and F1 in FIG. 2E), and (2) retracts the delivery sheath 204 and/or push member 202 proximally, thereby retracting the interventional device ID from the treatment site. During this time, in some embodiments, the guide catheter 206 remains fixed (e.g., by the housing 102) relative to the delivery sheath 204 and pull member 202. In such embodiments, as the lever 104 moves from the first position to the second position, the interventional device ID, delivery sheath 204, pull member 202, and at least a portion of the clot material PE are drawn proximally into the guide catheter 206.


As shown in FIG. 1B, moving the lever 104 from the second position to the first position (indicated by arrow A2 in FIG. 1B) creates a positive pressure (e.g., indicated by arrows F in FIG. 1B) in the first portion 314 and drainage portion 318 of the tubing system 300. The clot reservoir 306 prevents the positive pressure from affecting the aspiration lumen of the catheter system 200, thereby preventing backflow of fluid into the blood vessel BV at the treatment site. With respect to the catheter system 200, when the lever 104 is actuated from the second position to the first position, the RA device 100 does not engage the delivery sheath 204 or the push member 202 to move these components. Thus, the next time the lever 104 is actuated relative to the housing 102, the RA device 100 engages a new portion of the delivery sheath 204 and push member 202 such that the delivery sheath 204 and push member 202 are incrementally retracted proximally each time the lever 104 is “pumped” (e.g., moved from the first position toward the second position and then back toward the first position).


Depending on the age and size of the clot material PE, local anatomical and/or physiological conditions, and position of the interventional device ID relative to the clot material PE, the lever 104 can be pumped several times to fully extract the clot material PE and/or interventional device ID from the treatment site. For example, FIGS. 2D and 2E show the proximal movement of the delivery sheath 204 and pull member 202 after a first pump of the lever 104. FIGS. 2E and 2F show the proximal movement of the delivery sheath 204, pull member 202, and interventional device ID after a second pump of the lever 104 (e.g., including a second instance of pressure generation indicated by arrows F1 and F2 in FIGS. 2E and 2F, respectively). In some embodiments, the interventional device ID and the clot material PE can be fully withdrawn into the guide catheter 206 after a single pump of the lever 104. In other embodiments, such as those procedures where the interventional device ID is initially positioned such that a distal terminus of the interventional device ID is proximal of a distal terminus of the clot material PE (the clot material PE often originates in a vein of the patient's leg, and thus is cast into an elongated, worm-like shape), it can take several pumps of the lever 104 to fully withdraw the clot material PE into the guide catheter 206. Thus, in some embodiments, even when the interventional device ID is positioned within the guide catheter 206 such that a distal terminus of the interventional device ID is proximal of the distal terminus of the guide catheter 206, the lever 104 can be pumped several more times to continue to withdraw the clot material PE into the guide catheter 206 and the tubing system 300 (e.g., into the second portion 316, the clot reservoir 306, and/or the drainage portion 318).


Once the clot material PE is positioned within the guide catheter 206 such that a distal terminus of the clot material PE is proximal from a distal terminus of the guide catheter 206, the catheter system 200 can be withdrawn proximally (e.g., as indicated by arrow A3 in FIG. 2G) from the treatment site, and removed from the patient. However, sometimes, as shown in FIG. 2G, retracting the interventional device ID and delivery sheath 204 into the guide catheter 206 may not remove all of the clot material PE (or a desired amount of the clot material PE) from the blood vessel BV. That is, a single “pass” (e.g., a deployment of the interventional device ID and subsequent retraction of the interventional device ID into the guide catheter 206) may not adequately remove the clot material PE from the blood vessel BV. In such instances, the operator of the clot retrieval system 1 may wish to make another pass with the interventional device ID to remove all or a portion of the remaining clot material PE in the blood vessel BV.


To redeploy the interventional device ID, many conventional systems require that the entire catheter system, including the guide catheter 206, be fully removed from the patient (e.g., including a guide catheter). That is, if the once-deployed interventional device is reintroduced without fully removing and cleaning the catheter system, there is a significant risk that clot material and/or other contaminants from the catheter system will be reintroduced into the blood vessel of the patient during a second pass. As described in further detail below, the present technology advantageously allows for an interventional device to be redeployed without fully removing a guide catheter, and with a significantly reduced risk of reintroducing clot material and/or other contaminants into the blood vessel of the patient.


II. SELECTED EMBODIMENTS OF CLOT RESERVOIRS AND ASSOCIATED METHODS OF USE


FIGS. 3A-3C are a fully-exploded view, an isometric view, and a partially-exploded view of the clot reservoir 306 of the clot retrieval system 1. With reference to FIG. 3A, the clot reservoir 306 includes a housing 322 defining a chamber 323, a filter 321 configured to be positioned within the housing 322, and a cap assembly 330 configured to be coupled to the housing 322. The housing 322 can include a port 324 configured to be removably, fluidly coupled to the catheter system 200. In some embodiments, a tubing section 326 is coupled to the port 324 during priming of the clot retrieval system 1 and, as described in further detail below with reference to FIGS. 10 and 14, during flushing of the tubing system 300. In certain embodiments the tubing section 326 is semi-permanently coupled to the housing 322 and can be used to fluidly couple the housing 322 to the tubing system 300 and/or the catheter system 200.


In the embodiment illustrated in FIG. 3A, the cap assembly 330 includes a fluid connector (e.g., a barbed outlet) 332 for connecting to the tubing system 300 (e.g., to the tubing section 302d shown in FIGS. 1A and 1B), a nut 333 for releasably securing the cap assembly 330 to the housing 322 (e.g., via a threaded coupling), a first cap portion 334, and a second cap portion 338. In some embodiments, the fluid connector 332 is secured to the first cap portion 334 via an adhesive 331a, and the first cap portion 334 is secured to the nut 333 via a second adhesive 331b. In some embodiments, the first and second adhesives 331a, 331b are the same. The cap assembly 330 can further include a check valve assembly 335 positioned between the first and second cap portions 334, 338 and comprising a piston 336 and a spring 339 (e.g., a passivated compression spring). The check valve assembly 335 provides for one-way fluid flow through the clot reservoir 306, for example, from the catheter system 200 to the reservoir 320 (FIGS. 1A and 1B). The clot reservoir 306 can further include one or more O-rings 337 for sealing the various components.


In operation, blood and clot material flow into the clot reservoir 306 via the port 324 as the lever 104 of the RA device 100 is moved from the first position toward the second position. Clot material is captured within the housing 322 and inhibited from exiting through the cap assembly 330 by the filter 321 while blood is allowed to flow from the port 324 to the fluid connector 332. In particular, the filter 321 inhibits clot material from passing into the check valve assembly 335, which could inhibit function of the check valve assembly 335 and/or macerate the clot material and make it indistinguishable from or difficult to distinguish from other fluids (e.g., blood) aspirated and/or removed from the patient. The check valve assembly 335 subsequently inhibits backflow of fluid through the housing 322 via the fluid connector 332 as the lever 104 of the RA device 100 is moved from the second position toward the first position. With reference to FIGS. 3B and 3C, the cap assembly 330 can be decoupled from the housing 322 to, for example, permit an operator to remove clot material collected in the housing 322. Moreover, as shown, the housing 322 may be made of a transparent material that permits the operator to visualize material within the housing 322. As described in further detail below, in some embodiments, the operator can at least partially determine whether subsequent passes using the interventional device ID are necessary by visualizing the amount of clot material collected in the housing 322.


Additional details of the clot reservoir 306, and associated devices and methods, are described in Appendix A to this application.


III. SELECTED EMBODIMENTS OF ATTACHMENT/VALVE MEMBERS, AND ASSOCIATED DEVICES AND METHODS OF USE


FIG. 4 is a side view of an attachment/valve member 408 (“attachment member 408”) of the catheter system 200 and a second fluid control unit 410 of the tubing system 300 in accordance with embodiments of the present technology. The attachment member 408 and second fluid control unit 410 can have some features generally similar to the features of the attachment/valve member 208 and second fluid control unit 310, respectively, described above with reference to FIGS. 1A and 1B. For example, the attachment member 408 can be integral with or coupled to a proximal portion of the guide catheter 206 and configured to be detachably coupled to the RA device 100 (FIGS. 1A and 1B; e.g., via a snap-fit arrangement) to at least partially secure the catheter system 200 to the RA device 100. When secured to the RA device 100, the attachment member 408 can fluidly couple the lumen 205 (e.g., an aspiration lumen) of the guide catheter 206 to the tubing system 300 of the clot retrieval system 1 via the tubing section 302f. Likewise, the second fluid control unit 410 can be a clamp (“clamp 410”) that is externally operable to regulate the flow of liquid through the tubing section 302f. For example, the clamp 410 may be actuated (e.g., compressed or squeezed by the hand of an operator) to partially or fully restrict fluid flow through the tubing section 302f. In some embodiments, the clamp 410 includes features for locking or maintaining the clamp 410 in a position such that it restricts fluid flow through the tubing section 302f. FIG. 4 illustrates the clamp 410 in a position that permits fluid flow through the tubing section 302f.


As further shown in FIG. 4, the tubing system 300 can include a connector 417 that, for example, fluidly connects the tubing section 302f to other portions of the tubing system 300 (e.g., those shown in FIGS. 1A and 1B). In some embodiments, the connector 417 is a quick-release connector that enables rapid coupling/decoupling of the tubing section 302f to the clot reservoir 306 and/or other components of the tubing system 300. In some embodiments, the tubing system 300 can include a flush port adapter that can be removably coupled to the connector 417. The flush port adapter can be configured to, for example, fluidly connect a flushing device (e.g., a syringe) to the catheter system 200 so that the guide catheter 206 can further be flushed with a fluid (e.g., heparinized saline).



FIG. 5 is a side cross-sectional view of the attachment member 408 show in FIG. 4. As shown in the embodiment of FIG. 5, the attachment member 408 includes a body or housing 440 having a proximal opening 443a, a distal opening 443b, and a first lumen 441 extending between the proximal and distal openings 443a and 443b. The first lumen 441 further comprises a first portion 441a having a first diameter (e.g., a constant first diameter) and a second portion 441b having a second diameter greater than the first diameter. In some embodiments, the first diameter can be generally the same as the outer diameter of the guide catheter 206. The housing 443 further includes a branch portion 444 configured to be coupled to the tubing section 302f and having a second lumen 442 branching from the first lumen 441. In some embodiments, the second lumen 442 can have a relatively large diameter (e.g., between about 0.098 inch and 0.210 inch, about 0.210 inch, greater than 0.210 inch, etc.) to help inhibit clogging and/or collecting of clot material within the attachment member 408 during, for example, aspiration of the guide catheter 206.


As illustrated in the embodiment of FIG. 5, the attachment member 408 can further include a valve 445 within the second portion 441b of the first lumen 441. The valve 445 can be, for example, a hemostasis valve configured to maintain hemostasis by preventing fluid flow in the proximal direction through the proximal opening 443a of the attachment member 408 as the delivery sheath 204, the pull member 202, the guidewire, the interventional device ID, and/or other components of the catheter system 200 are inserted through the valve 445 for advancement to the treatment site in the blood vessel BV.



FIG. 6 is an isometric view of a first valve insert 650, such as a hub valve insert, in accordance with embodiments of the present technology. The first valve insert 650 is configured to be inserted at least partially into the first lumen 441 of the attachment member 408 (e.g., into the valve 445) through the proximal opening 443a of the attachment member 408. Accordingly, FIGS. 7A and 7B are a side view and a side cross-sectional view, respectively, of the first valve insert 650 inserted into the attachment member 408 in accordance with embodiments of the present technology.


Referring to FIG. 6, the first valve insert 650 includes a proximal portion 651a, a distal portion 651b extending from the proximal portion 651a, and a lumen 654. As illustrated in the embodiment of FIG. 6, the proximal portion 651a can optionally include one or more first engagement features (e.g., flanges, tabs, etc.) 652 configured to engage with the attachment member 408 of the of the catheter system 200 to securely position (e.g., lock, mate, flush, etc.) the first valve insert 650 within the attachment member 408. For example, in some embodiments, the first engagement features 652 can be configured to “snap” into (e.g., mate with) corresponding grooves on the attachment member 408. The proximal portion 651a can further include one or more second engagement features 653 (e.g., flanges, tabs, etc.) configured to be gripped by an operator to enable the operator to, for example, easily manipulate and/or position the first valve insert 650 within the attachment member 408.


Referring to FIGS. 6-7B together, the distal portion 651b of the first valve insert 650 is configured to be positioned at least partially within the second portion 441b of the first lumen 441 of the attachment member 408. For example, the first valve insert 650 can be advanced distally over the delivery sheath 204 and/or the guidewire of the catheter system 200 to the attachment member 408. Once inserted into the attachment member 408, the first valve insert 650 opens (e.g., exercises) the valve 445. In some embodiments, the lumen 654 of the distal portion 651b of the first valve insert 650 has a generally constant diameter that is generally the same as the first diameter of the first portion 441a of the first lumen 441 of the attachment member 408. In the embodiment illustrated in FIG. 7B, when the first valve insert 650 is within the attachment member 408, the distal portion 651b extends substantially or entirely through the second portion 441b of the first lumen 441 such that the lumen 654 of the first valve insert 650 and the second portion 441a of the first lumen 441 of the attachment member 408 together define a generally continuous lumen extending through the attachment member 408 (e.g., between the distal opening 443b of the attachment member 408 and a proximal terminus of the lumen 654).


In one aspect of the present technology, the continuous lumen formed by inserting the first valve insert 650 into the attachment member 408 can have a generally constant diameter along the length of the lumen configured to accommodate the outer diameter of the guide catheter 206. Accordingly, as described in further detail below, when a clot retaining portion of an interventional device and associated clot material are retracted proximally through the guide catheter 206, the interventional device ID does not greatly change shape (e.g., expand or compress) while passing through the attachment member 408 and the likelihood of clot material being retained within the attachment member 408 is greatly reduced.



FIG. 8 is a side view of a second valve insert 860 (e.g., an aspiration insert) in accordance with embodiments of the present technology. Similar to the first valve insert 650, the second valve insert 860 is configured to be inserted at least partially into the first lumen 441 of the attachment member 408 (e.g., through the valve 445) through the proximal opening 443a of the attachment member 408. Accordingly, FIG. 9 is a side view of the second valve insert 860 inserted into the attachment member 408 in accordance with embodiments of the present technology.


Referring to FIG. 8, the second valve insert 860 includes a proximal portion 861a, a distal portion 861b extending from the proximal portion 861a, and a lumen 864 extending through the second valve insert 860. As illustrated in the embodiment of FIG. 8, the distal portion 861b can optionally include one or more first engagement features (e.g., flanges, tabs, etc.) 862 configured to engage with the attachment member 408 to securely position (e.g., lock) the second valve insert 860 within the attachment member 408. For example, in some embodiments, the first engagement features 862 can be configured to “snap” into (e.g., mate with) corresponding grooves on the attachment member 408. The proximal portion 861a can further include one or more second engagement features 865a (e.g., flanges, tabs, etc.) configured to be gripped by an operator to enable the operator to, for example, easily manipulate and/or position the second valve insert 860 within the attachment member 408.


The proximal portion 861a can include one or more adjustment features 865 (labeled individually as adjustment features 865a and 865b) for adjusting a diameter of the lumen 864. For example, in some embodiments the second valve insert 860 is a Tuohy Borst Adapter that can be adjusted, via the one or more adjustment features 865, to seal the proximal opening 443a of the attachment member 408 by sealing the lumen 864 against a component of the catheter system 200 inserted therethrough. More particularly, referring to FIGS. 8 and 9 together, the distal portion 861b of the second valve insert 860 is configured to be positioned at least partially within the attachment member 408 (e.g., within the second portion 441b of the first lumen 441). For example, the second valve insert 860 can be advanced distally over the guidewire of the catheter system 200 to the attachment member 408. Once inserted into the attachment member 408, the second valve insert 860 opens (e.g., exercises) the valve 445. By tightening at least one of the adjustment features 865, at least a portion of the lumen 864 can be narrowed until a seal is formed between the second valve insert 860 and the guidewire or other component of the catheter system 200 positioned therein.


As described in further detail below, in some embodiments, the second valve insert 860 may more completely seal against components of the catheter system 200 than the valve 445 of the attachment member 408. Accordingly, use of the second valve insert 860 can improve the efficiency of aspiration of the guide catheter 206 using the RA device 100 (FIGS. 1A and 1B).



FIG. 10 is a flow diagram of a process or method 1000 for operating the clot retrieval system 1 including the attachment member 408 and the first and second valve inserts 650, 860 to remove clot material from within a blood vessel (e.g., a pulmonary blood vessel) of a human patient in accordance with embodiments of the present technology. Although some features of the method 1000 are described in the context of the embodiments shown in FIGS. 1A-9 for sake of illustration, one skilled in the art will readily understand that the method 1000 can be carried out using other suitable systems and/or devices.


The method 1000 includes engaging the interventional device ID of the catheter system 200 with the clot material PE in the blood vessel BV as, for example, described above with reference to FIGS. 2A-2D (block 1001). In particular, the attachment member 408 (FIGS. 4 and 5) of the catheter system 200 can be attached to the RA device 100, and the interventional device ID can be deployed within at least a portion of the clot material PE by proximally retracting the delivery sheath 204.


The method 1000 continues by proximally retracting the interventional device ID and associated clot material PE into the guide catheter 206 of the catheter system 200 until a distal terminus of the clot material PE is proximal from a distal terminus of the guide catheter 206 as, for example, described above with reference to FIGS. 2E-2G (block 1002). In particular, the RA device 100 can be pumped or cycled one or more times (e.g., one time, three times, five times, etc.) to retract the interventional device ID and/or delivery sheath 204 into the guide catheter 206 while simultaneously aspirating the lumen 205 of the guide catheter 206 to remove clot material PE and blood, which are drawn through the attachment member 408 and into the tubing system 300 (e.g., through the clot reservoir 306 to the reservoir 320).


In some embodiments, the interventional device ID can be retracted proximally into the guide catheter 206 without use of the RA device 100. For example, the operator can manually retract the interventional device ID and associated clot material PE into the guide catheter 206.


After initial deployment of the interventional device ID in blocks 1001 and 1002, the operator can determine whether it is necessary or desirable to redeploy the interventional device ID within the blood vessel BV of the patient in order to remove additional clot material PE that was not removed during a previous pass with the interventional device ID (block 1003). In some embodiments, the operator can visualize the amount of clot material PE collected in the clot reservoir 306 to at least partially determine whether another pass is needed. In other embodiments, the operator can rely on imaging (e.g., fluoroscopic imaging) of the blood vessel BV or other techniques known in the art to determine whether an additional pass is necessary. If another pass is not needed (e.g., the clot material PE was adequately removed), the operator can elect to withdraw the catheter system 200 from the patient (block 1004). If clot material PE remains in the vessel, the operator can prepare to redeploy the interventional device ID.


To redeploy the interventional device ID, the method 1000 includes positioning the first valve insert 650 (FIG. 6) and withdrawing the interventional device ID from the patient (block 1005). In particular, before positioning the first valve insert 650, the catheter system 200 can be decoupled from the RA device by (i) decoupling the attachment member 408 from the distal portion 100b of the RA device 100 and (ii) removing the delivery sheath 204 and/or guidewire from the channel 116. Additionally, in some embodiments, the clamp 410 can be actuated (e.g., closed) to prevent fluid flow from the guide catheter 206 into the tubing system 300 during withdrawal of the interventional device ID.


The first valve insert 650 can be advanced over the delivery sheath 204 and/or guidewire of the catheter system 200 until it is positioned (e.g., seated) at least partially within the attachment member 408 (FIGS. 7A and 7B). Once the first valve insert 650 is positioned within the attachment member 408, the interventional device ID and delivery sheath can be fully withdrawn from the patient. For example, in some embodiments, the operator may grip a portion of the delivery sheath 204 that is exposed proximally from the RA device 100 and pull the delivery sheath 204 and interventional device ID proximally through the guide catheter 206. In some embodiments, the first valve insert 650 is only positioned within the attachment member 408 when the interventional device ID is proximate the attachment member 408. That is, the operator may partially withdraw the delivery sheath 204 and interventional device ID within the guide catheter 206 before advancing the first valve insert 650 into position. In some embodiments, the delivery sheath 204 includes a marking (e.g., a specific color pattern) configured to indicate to the operator that the distal end of the delivery sheath 204 and/or the interventional device ID is near (e.g., proximally approaching) the attachment member 408. In certain embodiments, the guidewire of the catheter system 200 is pinned during withdrawal of the interventional device ID and the delivery sheath 204 such that the guidewire does not move relative to the interventional device ID and the delivery sheath 204. Therefore, in such embodiments, the guidewire does not need to be re-advanced to the treatment site prior to an additional pass.


In operation, the first valve insert 650 helps create a lumen of constant diameter through the attachment member 408 such that a diameter of the interventional device ID does not substantially change (e.g., expand and/or contract) as the interventional device ID is withdrawn proximally through the attachment member 408. In particular, the first valve insert 650 can effectively shield the interventional device ID from the valve 445 of the attachment member 408. Without the first valve insert 650, as the interventional device ID is withdrawn proximally it can expand within the attachment member 408 (e.g., as the interventional device ID passes through the second portion 441b of the first lumen 441) before being squeezed (e.g., radially collapsed) as it passes through the valve 445. Without the first valve insert 650, the valve 445 may strip (e.g., break off, shear, etc.) clot material PE that held by the interventional device ID. This can cause clot material PE to remain in the attachment member 408 after the interventional device ID is fully withdrawn from the patient, which presents a significant risk that remaining clot material PE will be reintroduced into the blood vessel BV of the patient if a second pass is made with the interventional device ID without fully removing the guide catheter 206 from the patient to enable cleaning of the guide catheter 206 and the attachment member 408. The first valve insert 650 of the present technology inhibits clot material PE engaged with the interventional device ID from being stripped by the valve 445 within the attachment member 408 and, therefore, enables a second pass with the interventional device ID to be made without removing the guide catheter 206 from the patient.


The method 1000 includes removing the first valve insert 650 and positioning the second valve insert 860 (FIG. 9) (block 1006). For example, the first valve insert 650 can be withdrawn proximally over the guidewire of the catheter system 200 and the second valve insert 860 can then be advanced distally over the guidewire until it is positioned within the attachment member 408. In some embodiments, the first valve insert 650 is removed and the second valve insert 860 is inserted into the attachment member 408 immediately after the delivery sheath 204 and interventional device ID are withdrawn from the patient. Prompt removal of the first valve insert 650 can restore function of the valve 445 and prevent excess blood from leaking through the lumen 654 of the first valve insert 650 once the delivery sheath 204 and interventional device ID are removed.


Positioning the second valve insert 860 further includes adjusting (tightening) the second valve insert 860 over the guidewire to seal the proximal opening 443a of the attachment member 408. In some embodiments, the method 1000 need not include positioning of the second valve insert 860. Instead, the valve 445 of the attachment member 408 may provide a suitable seal for subsequent aspiration steps. However, in some embodiments, use of the second valve insert 860 can provide a better seal between the guidewire of the catheter system 200 and the attachment member 408, and thus improve the efficiency of aspiration using the RA device 100.


The method 1000 includes aspirating the guide catheter 206 by, for example, pumping or cycling the lever 104 of the RA device 100 one or more times (block 1007). In embodiments where the clamp 410 was previously closed (e.g., at block 1005), prior to pumping the lever 104, the operator can actuate (e.g., open) the clamp 410 to permit fluid flow from the guide catheter 206 into the tubing system 300. Aspirating the guide catheter 206 removes any residual clot material PE remaining in the guide catheter 206. Accordingly, the residual clot material PE is not reintroduced into the blood vessel BV of the patient when the interventional device ID and delivery sheath 204 are subsequently advanced through the guide catheter 206 during another pass. In certain embodiments, the guide catheter 206 can further be flushed with a fluid (e.g., heparinized saline). For example, the connector 417 can be decoupled from the tubing system 300 and the fluid can be introduced from a flushing device (e.g., a syringe) through a flush port adapter coupled (e.g., semi-permanently coupled) to the connector 417.


In some embodiments, the guide catheter 206 can be aspirated without use of the RA device 100. For example, a syringe or other pressure source can be fluidly coupled directly to the connector 417 and used to aspirate the guide catheter 206. In such embodiments, opening of the clamp 410 fluidly connects the syringe to the lumen 205 of the guide catheter 206 and closing of the clamp 410 fluidly disconnects the syringe from the lumen 205 of the guide catheter 206. In some embodiments, the syringe or other pressure source can be pre-charged with a vacuum—such as by drawing a plunger of the syringe with the clamp 410 closed. The clamp 410 can then be opened to instantaneously or nearly instantaneously (e.g., immediately) apply the stored vacuum pressure to the tubing system 300 and to the lumen 205 of the guide catheter 206, thereby generating suction throughout the guide catheter 206. In particular, suction can be generated at a distal portion of the guide catheter 206. In one aspect of the present technology, pre-charging or storing the vacuum before applying the vacuum to the lumen 205 of the guide catheter 206 is expected to generate greater suction forces with a faster ramp time (and correspondingly greater fluid flow velocities) at and/or near a distal portion of the guide catheter 206 as compared to, for example, simply activating the pressure source of the RA device 100 by cycling the lever 104 of the RA device 100. These suction forces generated by application of the stored vacuum can be used to not only aspirate the guide catheter 206, but also to aspirate or otherwise remove some or all of the clot material PE remaining in the blood vessel BV after retraction of the interventional device ID.


The method 1000 includes flushing the tubing system 300 (block 1008). In some embodiments, flushing the tubing system 300 includes (i) actuating (e.g., closing) the clamp 410 to inhibit fluid flow from the guide catheter 206 into the tubing system 300, (ii) disconnecting the tubing section 326 of the clot reservoir 306 from the tubing section 302e and the connector 417 of the tubing system 300, (iii) placing the tubing section 326 into a container of fluid (e.g., saline), and (iv) pumping the lever 104 of the RA device 100 to draw the fluid through the tubing system 300. In some embodiments, the housing 322 of the clot reservoir 306 can be temporarily disconnected (e.g., unscrewed) from the cap assembly 330 so that the clot material PE in the clot reservoir 306 can be removed. In certain embodiments, the tubing system 300 need not be flushed prior to a second pass with the interventional device ID or another interventional device. In some embodiments, flushing the tubing system 300 can include attaching a syringe to the fluid connector 332 of the clot reservoir 306 and/or to the tubing section 302a of the tubing system 300 and using the syringe to generate a negative pressure to draw the fluid through the clot reservoir 306.


After the tubing system 300 has been flushed, the method 1000 can return to block 1001. In particular, the same interventional device ID and delivery sheath 204 can be cleaned and subsequently advanced through the guide catheter 206 and to the remaining clot material PE in the blood vessel BV. In some embodiments, a new interventional device and delivery sheath can be used for each pass to reduce the likelihood of contamination (e.g., reintroduction of clot material PE into the patient). Once the desired amount of clot material PE has been removed from the patient, the catheter system 200 may be fully withdrawn from the patient (block 1004).


In one aspect of the present technology, the method 1000 provides for multiple passes of an interventional device without requiring that the entire guide catheter be removed after each pass. Accordingly, the present technology allows for only a single insertion of a guide catheter during a procedure including multiple passes to remove clot material—increasing the speed of the procedure and reducing trauma to the patient since the guide catheter does not need to be reintroduced (e.g., advanced through the vasculature and past the heart) before each pass.


Moreover, in certain embodiments, the present technology can enable the guide catheter 206 to be relocated to an alternate treatment site within the patient without removing the guide catheter 206 from the patient and, therefore, without reintroducing the guide catheter 206 through the heart. For example, the guide catheter 206 can be relocated to another treatment site within the lungs including a treatment site in the opposite lung. More specifically, (i) a dilator can be reintroduced into the guide catheter 206, (ii) the guide catheter 206 can be withdrawn into the main pulmonary artery, (iii) the guidewire can be redirected to the new treatment site, (iv) the guide catheter 206 can be advanced over the guidewire to the new treatment site, and (v) the dilator can be removed.


Additional details of the systems, devices, and methods described above with reference to FIGS. 4-9 are provided in Appendix B to this application.


IV. OTHER SELECTED EMBODIMENTS OF ATTACHMENT/VALVE MEMBERS, AND ASSOCIATED DEVICES AND METHODS OF USE


FIG. 11 is a side view of an attachment/valve member 1108 (“attachment member 1108”) of the catheter system 200 and a second fluid control unit 1110 of the tubing system 300 in accordance with embodiments of the present technology. The attachment member 1108 and the second fluid control unit 1110 can have some features generally similar to the features of the attachment members 208, 408 and the second fluid control unit 310, 410, respectively, described above with reference to FIGS. 1A-10. For example, the attachment member 1108 can be integral with or coupled to a proximal portion of the guide catheter 206 and configured to be detachably coupled to the RA device 100 (FIGS. 1A and 1B; e.g., via a snap-fit arrangement) to at least partially secure the catheter system 200 to the RA device 100. When secured to the RA Device 100, the attachment member 1108 can fluidly connect the lumen 205 (e.g., an aspiration lumen) of the guide catheter 206 to the tubing system 300 of the clot retrieval system 1 via the tubing section 302f. Likewise, the second fluid control unit 1110 can be a stopcock (“stopcock 1110”) that is externally operable to regulate the flow of fluid through the tubing section 302f.


As further shown in FIG. 11, the tubing system 300 can include a connector 1117 for, for example, fluidly connecting the tubing section 302f and the stopcock 1110 to other portions of the tubing system 300 (e.g., those shown in FIGS. 1A and 1B). In some embodiments, the connector 1117 is a quick-release connector that enables rapid coupling/decoupling of the tubing section 302f and stopcock 1110 to other components of the tubing system 300.



FIG. 12 is a side view of the stopcock 1110 in accordance with embodiments of the present technology. In the embodiment illustrated in FIG. 12, the stopcock 1110 includes a grip member (e.g., a handle, a knob, etc.) 1211 that can be actuated (e.g., twisted by the hand of an operator) to partially or fully restrict fluid flow through the tubing section 302f. In some embodiments, the stopcock 1110 also includes an injection port 1212 (e.g., a needleless injection port) configured to receive a syringe or other fluid delivery member therethrough. In some embodiments, the injection port 1212 permits fluid to be introduced into the attachment member 1108 and the guide catheter 206 without requiring that a connector 1117 be decoupled from the tubing system 300. For example, in some embodiments, an operator can actuate the stopcock 1110 (e.g., twist the grip member 1211) to close the stopcock 1110 and subsequently introduce a syringe at the injection port 1212 to flush the guide catheter 206 with a fluid (e.g., saline) introduced via the syringe.



FIGS. 13A and 13B are side cross-sectional views of the attachment member 1108 in a first configuration and a second configuration, respectively, in accordance with embodiments of the present technology. The attachment member 1108 can be, for example, a garrote valve (e.g., a hemostasis valve) as disclosed in provisional U.S. Patent Application No. 62/554,931, filed Sep. 6, 2017, and titled “HEMOSTASIS VALVES AND METHODS OF USE,” which is reproduced in Appendix D to this application, and which is incorporated herein by reference in its entirety.


In particular, referring to FIGS. 13A and 13B together, the attachment member 1108 can include a housing 1370 having a proximal opening 1373a and a distal opening 1373b, and defining a first lumen (e.g., an interior channel) 1371 extending between the proximal and distal openings 1373a, 1373b. The housing 1370 further includes a branch portion 1380 configured to be coupled to the tubing section 302f and defining a second lumen 1381 branching from the first lumen 1371. In some embodiments, the second lumen 1381 can have a relatively large diameter (e.g., between about 0.098 inch and 0.210 inch, about 0.210 inch, greater than 0.210 inch, etc.) to help inhibit clogging and/or collection of clot material within the attachment member 1108 during, for example, aspiration of the guide catheter 206. In one aspect of the present technology, the first lumen 1371 can have a generally constant diameter along its length.


As shown, a tubular member (e.g., an elongate member) 1372 can extend at least partially through the first lumen 1371 to define a central lumen 1374 that is generally coaxial with the first lumen 1371. In some embodiments, the tubular member 1372 can comprise a compliant tubular structure (e.g., a silicon tube) that can be, for example, a thin-walled compliant tubular structure. The thin-walled structure of the tubular member 1372 can facilitate the collapse, and specifically the uniform collapse of the tubular member 1372 and sealing of the tubular member 1372. For example, the attachment member 1108 can further include an actuation mechanism 1375 coupled to the tubular member 1372 and configured to collapse and seal the tubular member 1372 via compression and/or constriction of one or more filaments 1376 coupled to the tubular member 1372.


More specifically, in some embodiments, the actuation mechanism 1375 can be a manual actuator such as one or more buttons 1378. Depression or release of the buttons can, in some embodiments, facilitate sealing of the tubular member 1372 around tools or instruments of a wide range of sizes and/or diameters that fit through the tubular member 1372. For example, FIG. 13A illustrates the attachment member 1108 with the actuation mechanism 1375 in the first configuration in which the tubular member 1372 is in a collapsed and/or sealed state having a minimum diameter (e.g., conformed to a diameter of a portion of a catheter system inserted therethrough). In the embodiment shown in FIG. 13A, the actuation mechanism 1375 is biased (e.g., by one or more springs 1377) to maintain the tubular member 1372 in the collapsed state. Specifically, in the first configuration, the actuation mechanism 1375 can tighten the filament 1376 to constrict or compress the tubular member 1372 to seal the central lumen 1374 of the tubular member 1372. Thus, when the buttons 1378 are not depressed, the attachment member 1108 can provide a hemostatic seal.


As shown in the embodiment of FIG. 13B, the attachment member 1108 is in an expanded (e.g., open) and/or unsealed state having a maximum diameter (e.g., a diameter generally the same as the first lumen 1371). More particularly, one or more of the buttons 1378 may be depressed to, for example, loosen the filament 1376 and allow expansion of the tubular member 1372 to unseal the central lumen 1374 of the tubular member 1372.


Accordingly, the actuation mechanism 1375 and tubular member 1372 of the attachment member 1108 provide for sealing of the attachment member 1108 around, for example, various components of the catheter system 200 (e.g., the delivery sheath 204, the pull member 202, the guidewire, the interventional device ID, etc.) that are inserted through the attachment member 1108 for advancement to the treatment site in the blood vessel BV. Moreover, in the second configuration, the central lumen 1374 of the tubular member 1372 and the first lumen 1371 of the housing 1370 can together provide a continuous lumen of generally constant diameter. As described above, such a constant diameter can prevent clot material PE associated with the interventional device ID from getting stuck in (e.g., remaining in) the attachment member 1108 as the interventional device ID is retracted through the attachment member 1108—thus minimizing the risk of reintroducing clot material to the patient upon a second pass using the interventional device ID (or another interventional device).



FIG. 14 is a flow diagram of a process or method 1400 for operating the clot retrieval system 1 including the attachment member 1108 to remove clot material from within a blood vessel (e.g., a pulmonary blood vessel) of a human patient in accordance with embodiments of the present technology. Although some features of the method 1400 are described in the context of the embodiments shown in FIGS. 1A, 1B, and 11-13 for sake of illustration, one skilled in the art will readily understand that the method 1400 can be carried out using other suitable systems and/or devices.


The method 1400 includes engaging the interventional device ID of the catheter system 200 with the clot material PE in the blood vessel BV as, for example, described above with reference to FIGS. 2A-2D (block 1401). In particular, the attachment member 1108 of the catheter system 200 can be coupled to the RA device 100, and the interventional device ID can be deployed within at least a portion of the clot material PE by proximally retracting the delivery sheath 204 relative to the interventional device ID.


The method 1400 continues by proximally retracting the interventional device ID and associated clot material PE into the guide catheter 206 of the catheter system 200 until a distal terminus of the clot material PE is proximal from a distal terminus of the guide catheter 206 as, for example, described above with reference to FIGS. 2E-2G (block 1402). In particular, the RA device 100 can be pumped or cycled one or more times (e.g., one time, three times, five times, etc.) to retract the interventional device ID and/or delivery sheath 204 into the guide catheter 206 while simultaneously aspirating the lumen 205 of the guide catheter 206 to remove clot material PE and blood, which are drawn through the attachment member 1108 of the catheter system 200 and into the tubing system 300 (e.g., through the clot reservoir 306 to the reservoir 320).


In some embodiments, the interventional device ID can be retracted proximally into the guide catheter 206 without use of the RA device 100. For example, the operator can manually retract the interventional device ID and associated clot material PE into the guide catheter 206.


After the initial deployment of the interventional device ID in blocks 1401 and 1402, the operator can determine whether it is necessary or desirable to redeploy the interventional device ID within the blood vessel BV of the patient in order to remove additional clot material PE that was not removed during a previous pass with the interventional device ID (block 1403). In some embodiments, the operator can visualize the amount of clot material PE collected in the clot reservoir 306 to at least partially determine whether another pass is needed. In other embodiments, the operator can rely on imaging (e.g., fluoroscopic imaging) of the blood vessel BV or other techniques known in the art to determine whether an additional pass is necessary. If another pass is not needed (e.g., the clot material PE was adequately removed), the operator can elect to withdraw the catheter system 200 from the patient at block 1404. If clot material PE remains in the vessel, the operator can prepare to redeploy the interventional device ID.


To redeploy the interventional device ID, the method 1400 includes withdrawing the interventional device ID from the patient (block 1405). In particular, before withdrawing the interventional device ID, the catheter system 200 can be decoupled from the RA device by (i) decoupling the attachment member 1108 from the distal portion 100b of the RA device 100 and (ii) removing the delivery sheath 204 and/or guidewire from the channel 116 of the RA device 100. Additionally, in some embodiments, the stopcock 1110 can be actuated (e.g., twisted closed) to prevent fluid flow from the guide catheter 206 into the tubing system 300 during withdrawal of the interventional device ID.


The delivery sheath 204 and/or another component of the catheter system 200 may then be manually (e.g., by the operator) or automatically pulled proximally to withdraw the interventional device ID from the patient. Before the interventional device ID and associated clot material PE are withdrawn through the attachment member 1108, the actuation mechanism 1375 of the attachment member 1108 can be actuated (e.g., by depressing the buttons 1378) to move the tubular member 1372 to the second configuration (e.g., to open the tubular member 1372) such that the central lumen 1374 of the tubular member 1372 and the first lumen 1371 of the housing 1370 together provide a continuous lumen of generally constant diameter. Accordingly, the interventional device ID can be fully withdrawn (e.g., retracted proximally) through the attachment member 1108 without causing a significant amount of clot material PE associated with the interventional device ID to remain in the attachment member 1108—thus minimizing the risk of reintroducing clot material to the patient upon an additional pass using the interventional device ID (or another interventional device). Moreover, in certain embodiments, the guidewire of the catheter system 200 is pinned during withdrawal of the interventional device ID and the delivery sheath 204 such that the guidewire does not move relative to the interventional device ID and the delivery sheath 204. Therefore, in such embodiments, the guidewire does not need to be re-advanced to the treatment site prior to an additional pass.


Once the interventional device ID has been fully removed from the guide catheter 206 and the attachment member 1108, the attachment member 1108 can be returned to the first (e.g., sealed) configuration by, for example, releasing the buttons 1378. Next, the method includes aspirating the guide catheter 206 by, for example, pumping or cycling the lever 104 of the RA device 100 one or more times (block 1406). In embodiments where the stopcock 1110 was previously closed (e.g., at block 1405), prior to pumping the lever 104, the stopcock 1110 can be opened to permit fluid flow from the guide catheter 206 into the tubing system 300. Aspirating the guide catheter 206 removes any residual clot material PE remaining in the guide catheter 206. Accordingly, the residual clot material PE is not reintroduced into the blood vessel BV of the patient when the interventional device ID and delivery sheath 204 (or another interventional device ID) are subsequently advanced through the guide catheter 206 during another pass. In certain embodiments, the guide catheter 206 can further be flushed with a fluid (e.g., heparinized saline). For example, the fluid can be introduced through the injection port 1212 while simultaneously pressing the buttons 1378 of the attachment member 1108. In certain embodiments, the stopcock 1110 can be closed (e.g., at block 1406), and a syringe can be connected to the injection port 1212 and used to generate a negative pressure prior to opening the stopcock 1110 to permit fluid flow from the guide catheter 206 into the syringe.


In some embodiments, the guide catheter 206 can be aspirated without use of the RA device 100. For example, a syringe or other pressure source can be fluidly coupled directly to the connector 1117 and used to aspirate the guide catheter 206. In such embodiments, opening of the stopcock 1110 fluidly connects the syringe to the lumen 205 of the guide catheter 206 and closing of the stopcock 1110 fluidly disconnects the syringe from the lumen 205 of the guide catheter 206. In some embodiments, the syringe or other pressure source can be pre-charged with a vacuum— such as by drawing a plunger of the syringe with the stopcock 1110 closed. The stopcock 1110 can then be opened to instantaneously or nearly instantaneously (e.g., immediately) apply the stored vacuum pressure to the tubing system 300 and to the lumen 205 of the guide catheter 206, thereby generating suction throughout the guide catheter 206. In particular, suction can be generated at a distal portion of the guide catheter 206. In one aspect of the present technology, pre-charging or storing the vacuum before applying the vacuum to the lumen 205 of the guide catheter 206 is expected to generate greater suction forces with a faster ramp time (and correspondingly greater fluid flow velocities) at and/or near a distal portion of the guide catheter 206 as compared to, for example, simply activating the pressure source of the RA device 100 by cycling the lever 104 of the RA device 100. These suction forces generated by application of the stored vacuum can be used to not only aspirate the guide catheter 206, but also to aspirate or otherwise remove some or all of the clot material PE remaining in the blood vessel BV after retraction of the interventional device ID.


The method 1400 includes flushing the tubing system 300 (block 1407). In some embodiments, flushing the tubing system 300 includes (i) closing the stopcock 1110 to inhibit fluid flow from the guide catheter 206 into the tubing system 300, (ii) disconnecting the tubing section 326 of the clot reservoir 306 from the tubing section 300e of the tubing system 300, (iii) placing the tubing section 326 into a container of fluid (e.g., saline), and (iv) pumping the lever 104 of the RA device 100 to draw the fluid through the tubing system 300. In some embodiments, the housing 322 of the clot reservoir 306 can be temporarily decoupled (e.g., unscrewed) from the cap assembly 330 so that the clot material PE in the clot reservoir 306 can be removed. In certain embodiments, the tubing system 300 need not be flushed prior to an additional pass with the interventional device ID. In some embodiments, flushing the tubing system 300 can include attaching a syringe to the fluid connector 332 of the clot reservoir 306 and/or to the tubing section 302a of the tubing system 300 and using the syringe to generate a negative pressure to draw the fluid through the clot reservoir 306.


After the tubing system 300 has been flushed, the method 1400 can return to block 1401. In particular, the same interventional device ID and delivery sheath 204 can be cleaned and subsequently advanced through the guide catheter 206 and to the remaining clot material PE in the blood vessel. In some embodiments, a new interventional device ID and delivery sheath 204 can be used for each pass to reduce the likelihood of contamination (e.g., reintroduction of clot material PE). Once the desired amount of clot material PE has been removed from the patient, the catheter system 200 may be fully withdrawn from the patient (block 1404).


In one aspect of the present technology, the method 1400 provides for multiple passes of an interventional device without requiring that the entire guide catheter be removed after each pass. Accordingly, the present technology allows for only a single insertion of a guide catheter during a procedure including multiple passes to remove clot material—increasing the speed of the procedure and reducing trauma to the patient since the guide catheter does not need to be reintroduced (e.g., advanced through the vasculature and past the heart) before each pass.


Moreover, in certain embodiments, the present technology can enable the guide catheter 206 to be relocated to an alternate treatment site within the patient without removing the guide catheter 206 from the patient and, therefore, without reintroducing the guide catheter 206 through the heart. For example, the guide catheter 206 can be relocated to another treatment site within the lungs including a treatment site in the opposite lung. More specifically, (i) a dilator can be reintroduced into the guide catheter 206, (ii) the guide catheter 206 can be withdrawn into the main pulmonary artery, (iii) the guidewire can be redirected to the new treatment site, (iv) the guide catheter 206 can be advanced over the guidewire to the new treatment site, and (v) the dilator can be removed.


Additional details of the systems, devices, and methods described above with reference to FIGS. 11-14 are provided in Appendix C to this application.


V. EXAMPLES

1. A method for the intravascular treatment of clot material from a treatment site within a blood vessel of a human patient, the method comprising:

    • engaging a first interventional device with the clot material at the treatment site in the blood vessel;
    • retracting the first interventional device and a portion of the clot material into a distal portion of an elongated shaft;
    • inserting a first valve insert into an attachment member coupled to a proximal portion of the elongated shaft;
    • withdrawing the first interventional device and the portion of the clot material proximally through (a) the elongated shaft, (b) the attachment member, and (c) the first valve insert;
    • inserting a second valve insert into the attachment member instead of the first valve insert;
    • aspirating the elongated shaft; and
    • advancing a second interventional device distally through the elongated shaft to the treatment site.


2. The method of example 1 wherein, after inserting the first valve insert into the attachment member, the first valve insert and the attachment member together define a lumen having a generally constant diameter.


3. The method of example 2 wherein the diameter of the lumen is generally the same as the diameter of the elongated shaft.


4. The method of any one of examples 1-3 wherein inserting the first valve insert into the attachment member includes exercising a valve of the attachment member.


5. The method of any one of examples 1-4, further comprising actuating the second valve insert to seal the attachment member.


6. The method of any one of examples 1-5 wherein the first interventional device and the second interventional device are the same interventional device, and wherein the method further comprises cleaning the interventional device to remove the portion of the clot material.


7. The method of any one of examples 1-6, further comprising engaging the second interventional device with remaining clot material at the treatment site in the blood vessel.


8. The method of any one of examples 1-7 wherein aspirating the elongated shaft includes aspirating, into the elongated shaft, at least a portion of clot material remaining at the treatment site in the blood vessel.


9. The method of example 8 wherein aspirating the elongated shaft includes—

    • coupling a syringe to the elongated shaft via a fluid control unit, wherein opening of the fluid control unit fluidly connects the syringe to the elongated shaft, and wherein closing of the fluid control device fluidly disconnects the syringe from the elongated shaft;
    • drawing a plunger of the syringe to generate a vacuum while the fluid control unit is closed; and
    • opening the fluid control unit to apply the vacuum to the elongated shaft to thereby aspirate the portion of the remaining clot material into the elongated shaft.


10. The method of example 9 wherein the fluid control unit is a clamp.


11. A method for the intravascular treatment of clot material from a treatment site within a blood vessel of a human patient, the method comprising:

    • engaging a first interventional device with the clot material at the treatment site in the blood vessel;
    • retracting the first interventional device and a portion of the clot material into a distal portion of an elongated shaft;
    • withdrawing the interventional device and the portion of the clot material from the blood vessel through the elongated shaft and an attachment member coupled thereto, including—
      • before withdrawing the interventional device through the attachment member, actuating the attachment member to move the attachment member from a first configuration in which a lumen of the attachment member is sealed to a second configuration in which the lumen of the attachment member is open;
      • after withdrawing the interventional device through the attachment member, actuating the attachment member to return the attachment member to the first configuration from the second configuration;
    • aspirating the elongated shaft; and
    • advancing a second interventional device distally through the elongated shaft to the treatment site.


12. The method of example 11 wherein actuating the attachment member includes pressing one or more buttons on the attachment member.


13. The method of example 11 or 12 wherein in the second configuration, the lumen of the attachment member has a generally constant diameter.


14. The method of example 13 wherein the diameter of the lumen is generally the same as a diameter of the elongated shaft.


15. The method of any one of examples 11-14 wherein the first interventional device and the second interventional device are the same interventional device, and wherein the method further comprises cleaning the interventional device to remove the portion of the clot material.


16. The method of any one of examples 11-15, further comprising engaging the second interventional device with remaining clot material in the blood vessel.


17. The method of one of examples 11-16 wherein aspirating the elongated shaft includes—

    • coupling a syringe to the elongated shaft via a stopcock, wherein opening of the stopcock fluidly connects the syringe to the elongated shaft, and wherein closing of the stopcock fluidly disconnects the syringe from the elongated shaft;
    • drawing a plunger of the syringe to generate a vacuum while the stopcock is closed; and
    • opening the stopcock to apply the vacuum to the elongated shaft to thereby aspirate, into the elongated shaft, at least a portion of clot material remaining at the treatment site in the blood vessel.


18. A method for the intravascular treatment of clot material from a treatment site within a blood vessel of a human patient, the method comprising:

    • engaging an interventional device with the clot material at the treatment site in the blood vessel;
    • retracting the interventional device and a portion of the clot material into a distal portion of a lumen of an elongated shaft;
    • unsealing an attachment member coupled to a proximal portion of the elongated shaft;
    • withdrawing the interventional device and the portion of the clot material through the lumen of the elongated shaft and through the attachment member;
    • sealing the attachment member;
    • aspirating the elongated shaft; and
    • advancing the same or a different interventional device distally through the lumen of the elongated shaft to the treatment site.


19. The method of example 18 wherein unsealing the attachment member includes exercising a valve of the attachment member such that a lumen of the attachment member has a diameter that is about equal to a diameter of the lumen of the elongated shaft.


20. The method of example 18 or 19, further comprising:

    • engaging the same or the different interventional device with clot material remaining in the blood vessel; and
    • retracting the same or the different interventional device interventional device and a portion of the remaining clot material into the distal portion of the lumen of the elongated shaft;
    • unsealing the attachment member; and
    • withdrawing the same or the different interventional device and the portion of the remaining clot material through the lumen of the elongated shaft and through the attachment member.


VI. CONCLUSION

The above detailed descriptions of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise form disclosed above. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology as those skilled in the relevant art will recognize. For example, although steps are presented in a given order, alternative embodiments may perform steps in a different order. The various embodiments described herein may also be combined to provide further embodiments.


From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but well-known structures and functions have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments of the technology. Where the context permits, singular or plural terms may also include the plural or singular term, respectively.


Moreover, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. Further, while advantages associated with some embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.

Claims
  • 1. An aspiration system, comprising: a vacuum source;connection tubing fluidically coupled to the vacuum source;a catheter fluidically coupled to the vacuum source;a filter chamber coupled to the connection tubing at a location apart from the vacuum source, wherein the filter chamber comprises a housing and a filter within the housing, and wherein the housing includes— a first end portion;a second end portion;a port at the first end portion configured to be fluidically coupled to the catheter; anda fluid connector at the second end portion configured to be coupled to the connection tubing; andwherein the filter is in the housing along a first flow path between the port and the fluid connector, and whereinthe catheter is fluidically coupled to the vacuum source via the filter chamber along a second flow path;a flow controller fluidically coupling the filter chamber to the catheter, wherein the flow controller is along the second flow path between the filter chamber and the catheter such that flow from the catheter to the filter chamber is controlled proximate to the catheter; anda hemostasis valve fluidically coupled to the catheter along a third flow path different than the second flow path, wherein the hemostasis valve is configured to maintain hemostasis by preventing proximal fluid flow along the third flow path when an interventional device is inserted through the hemostasis valve and the catheter.
  • 2. The aspiration system of claim 1 wherein the flow controller comprises a flow control unit between the filter chamber and the catheter.
  • 3. The aspiration system of claim 2 wherein the flow control unit comprises a stopcock valve.
  • 4. The aspiration system of claim 2 wherein the flow control unit comprises a clamp.
  • 5. The aspiration system of claim 1, further comprising: a check valve in the housing along the first flow path, the check valve being configured to allow flow in a direction from the port toward the fluid connector but prevent flow in a direction from the fluid connector to the port.
  • 6. The aspiration system of claim 5 wherein the check valve is positioned between the fluid connector and the filter.
  • 7. The aspiration system of claim 6 wherein the flow controller comprises a valve between the filter chamber and the housing.
  • 8. The aspiration system of claim 1, further comprising a check valve.
  • 9. The aspiration system of claim 1, further comprising a check valve in the housing between the second end portion and the filter.
  • 10. The aspiration system of claim 1 wherein the first flow path is fluidically connected in serial to the second flow path.
  • 11. An aspiration system, comprising: a vacuum source;connection tubing fluidically coupled to the vacuum source;a filter chamber coupled to the connection tubing at a location apart from the vacuum source, wherein the filter chamber comprises a housing and a filter within the housing, and wherein the housing includes— a first end portion;a second end portion;a port at the first end portion configured to be fluidically coupled to the catheter; anda fluid connector at the second end portion configured to be coupled to the connection tubing; andwherein the filter is in the housing along a first flow path between the port at the first end portion and the fluid connector at the second end portion;a check valve in the housing along the first flow path, wherein the check valve is positioned between the fluid connector and the filter, and wherein the check valve is configured to allow flow in a direction from the port toward the fluid connector but prevent flow in a direction from the fluid connector to the port;a catheter fluidically coupled to the vacuum source via the filter chamber along a second flow path; anda flow controller fluidically coupling the filter chamber to the catheter, wherein the flow controller is along the second flow path between the filter chamber and the catheter such that flow from the catheter to the filter chamber is controlled proximate to the catheter.
  • 12. The aspiration system of claim 11 wherein the flow controller comprises a valve between the filter chamber and the housing.
  • 13. The aspiration system of claim 11 wherein the first flow path is fluidically connected in serial to the second flow path.
  • 14. The aspiration system of claim 11, further comprising a hemostasis valve fluidically coupled to the catheter along a third flow path different than the second flow path, wherein the hemostasis valve is configured to maintain hemostasis by preventing proximal fluid flow along the third flow path when an interventional device is inserted through the hemostasis valve and the catheter.
  • 15. An aspiration system, comprising: a vacuum source;connection tubing fluidically coupled to the vacuum source;a filter chamber coupled to the connection tubing at a location apart from the vacuum source, wherein the filter chamber comprises a housing and a filter within the housing, wherein the filter has a first end portion and a second portion, and wherein the second end portion is configured to be coupled to the connection tubing;a catheter fluidically coupled to the vacuum source via the filter chamber along a flow path;a flow controller fluidically coupling the filter chamber to the catheter, wherein the flow controller is along the flow path between the filter chamber and the catheter such that flow from the catheter to the filter chamber is controlled proximate to the catheter; anda check valve in the housing between the second end portion and the filter.
  • 16. The aspiration system of claim 15 wherein the flow path is a first flow path, and further comprising a hemostasis valve fluidically coupled to the catheter along a second flow path different than the first flow path, wherein the hemostasis valve is configured to maintain hemostasis by preventing proximal fluid flow along the second flow path when an interventional device is inserted through the hemostasis valve and the catheter.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No. 17/498,642, filed on Oct. 11, 2021, and titled “SINGLE INSERTION DELIVERY SYSTEM FOR TREATING EMBOLISM AND ASSOCIATED SYSTEMS AND METHODS,” which is a continuation of U.S. patent application Ser. No. 16/258,344, filed on Jan. 25, 2019, and titled “SINGLE INSERTION DELIVERY SYSTEM FOR TREATING EMBOLISM AND ASSOCIATED SYSTEMS AND METHODS,” which is now issued as U.S. Pat. No. 11,154,314, which claims the benefit of U.S. Provisional Patent Application No. 62/622,691, filed on Jan. 26, 2018, and titled “SINGLE INSERTION DELIVERY SYSTEM FOR TREATING EMBOLISM AND ASSOCIATED SYSTEMS AND METHODS,” each of which are incorporated herein by reference in their entirety.

US Referenced Citations (842)
Number Name Date Kind
1101890 Tunstead Jun 1914 A
2846179 Monckton Aug 1958 A
2955592 Maclean Oct 1960 A
3088363 Sparks May 1963 A
3197173 Taubenheim Jul 1965 A
3416531 Edwards Dec 1968 A
3435826 Fogarty Apr 1969 A
3515137 Santomieri Jun 1970 A
3675657 Gauthier Jul 1972 A
3860006 Patel Jan 1975 A
3892161 Sokol Jul 1975 A
3923065 Nozick et al. Dec 1975 A
4030503 Clark, III Jun 1977 A
4034642 Iannucci et al. Jul 1977 A
4222380 Terayama Sep 1980 A
4243040 Beecher Jan 1981 A
4287808 Leonard et al. Sep 1981 A
4324262 Hall Apr 1982 A
4393872 Reznik et al. Jul 1983 A
4469100 Hardwick Sep 1984 A
4523738 Raftis et al. Jun 1985 A
4551862 Haber Nov 1985 A
4604094 Shook Aug 1986 A
4611594 Grayhack et al. Sep 1986 A
4643184 Mobin-Uddin Feb 1987 A
4646736 Auth et al. Mar 1987 A
4650466 Luther Mar 1987 A
4776337 Palmaz Oct 1988 A
4790812 Hawkins, Jr. et al. Dec 1988 A
4863440 Chin et al. Sep 1989 A
4870953 DonMichael et al. Oct 1989 A
4883458 Shiber Nov 1989 A
4886062 Wiktor Dec 1989 A
4890611 Monfort et al. Jan 1990 A
4898575 Fischell et al. Feb 1990 A
4946440 Hall Aug 1990 A
4960259 Sunnanvader et al. Oct 1990 A
4978341 Niederhauser Dec 1990 A
4981478 Evard et al. Jan 1991 A
5059178 Ya Oct 1991 A
5100423 Fearnot Mar 1992 A
5127626 Hilal et al. Jul 1992 A
5129910 Phan et al. Jul 1992 A
5135484 Wright Aug 1992 A
5154724 Andrews Oct 1992 A
5158533 Strauss et al. Oct 1992 A
5158564 Schnepp-Pesch et al. Oct 1992 A
5192274 Bierman Mar 1993 A
5192286 Phan et al. Mar 1993 A
5192290 Hilal Mar 1993 A
5197485 Grooters Mar 1993 A
5234403 Yoda et al. Aug 1993 A
5244619 Burnham Sep 1993 A
5256150 Quiachon et al. Oct 1993 A
5329923 Lundquist Jul 1994 A
5330436 Heidmueller Jul 1994 A
5360417 Gravener et al. Nov 1994 A
5364345 Lowery et al. Nov 1994 A
5376101 Green et al. Dec 1994 A
5383887 Nadal Jan 1995 A
5389100 Bacich et al. Feb 1995 A
5391152 Patterson et al. Feb 1995 A
5419774 Willard et al. May 1995 A
5421824 Clement et al. Jun 1995 A
5443443 Shiber Aug 1995 A
5456667 Ham et al. Oct 1995 A
5476450 Ruggio Dec 1995 A
5490859 Mische et al. Feb 1996 A
5496365 Sgro Mar 1996 A
5527326 Hermann et al. Jun 1996 A
5549626 Miller et al. Aug 1996 A
5591137 Stevens Jan 1997 A
5639276 Weinstock et al. Jun 1997 A
5653684 Laptewicz et al. Aug 1997 A
5662703 Yurek et al. Sep 1997 A
5746758 Nordgren et al. May 1998 A
5749858 Cramer May 1998 A
5769816 Barbut et al. Jun 1998 A
5782817 Franzel et al. Jul 1998 A
5800457 Gelbfish Sep 1998 A
5827229 Auth et al. Oct 1998 A
5846251 Hart Dec 1998 A
5860938 Lafontaine et al. Jan 1999 A
5873866 Kondo et al. Feb 1999 A
5873882 Straub et al. Feb 1999 A
5876414 Straub Mar 1999 A
5895406 Gray et al. Apr 1999 A
5908435 Samuels Jun 1999 A
5911710 Barry et al. Jun 1999 A
5911733 Parodi Jun 1999 A
5911754 Kanesaka et al. Jun 1999 A
5941869 Patterson et al. Aug 1999 A
5947985 Ram Sep 1999 A
5954737 Lee Sep 1999 A
5971938 Hart et al. Oct 1999 A
5971958 Zhang Oct 1999 A
5972019 Engelson et al. Oct 1999 A
5974938 Lloyd Nov 1999 A
5989233 Yoon Nov 1999 A
5993483 Gianotti Nov 1999 A
6017335 Burnham Jan 2000 A
6030397 Moneti et al. Feb 2000 A
6059814 Ladd May 2000 A
6066158 Engelson et al. May 2000 A
6068645 Tu May 2000 A
6126635 Simpson et al. Oct 2000 A
6142987 Tsugita Nov 2000 A
6146396 Konya et al. Nov 2000 A
6146403 St. Germain Nov 2000 A
6152144 Lesh et al. Nov 2000 A
6152946 Broome et al. Nov 2000 A
6156055 Ravenscroft Dec 2000 A
6159230 Samuels Dec 2000 A
6165196 Stack et al. Dec 2000 A
6168579 Tsugita Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6228060 Howell May 2001 B1
6238412 Dubrul et al. May 2001 B1
6245078 Ouchi Jun 2001 B1
6245089 Daniel et al. Jun 2001 B1
6254571 Hart Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6264663 Cano Jul 2001 B1
6306163 Fitz Oct 2001 B1
6322572 Lee Nov 2001 B1
6350271 Kurz et al. Feb 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6364895 Greenhalgh Apr 2002 B1
6368339 Amplatz Apr 2002 B1
6383205 Samson et al. May 2002 B1
6402771 Palmer et al. Jun 2002 B1
6413235 Parodi Jul 2002 B1
6423032 Parodi Jul 2002 B2
6432122 Gilson et al. Aug 2002 B1
6451036 Heitzmann et al. Sep 2002 B1
6458103 Albert et al. Oct 2002 B1
6475236 Roubin et al. Nov 2002 B1
6485502 Don Michael Nov 2002 B2
6508782 Evans et al. Jan 2003 B1
6511492 Rosenbluth et al. Jan 2003 B1
6514273 Voss et al. Feb 2003 B1
6530923 Dubrul et al. Mar 2003 B1
6530935 Wensel et al. Mar 2003 B2
6540722 Boyle et al. Apr 2003 B1
6544276 Azizi Apr 2003 B1
6544278 Vrba et al. Apr 2003 B1
6544279 Hopkins et al. Apr 2003 B1
6551342 Shen et al. Apr 2003 B1
6564828 Ishida May 2003 B1
6569181 Burns May 2003 B1
6575995 Huter et al. Jun 2003 B1
6589263 Hopkins et al. Jul 2003 B1
6596011 Johnson et al. Jul 2003 B2
6602271 Adams et al. Aug 2003 B2
6605074 Zadno-azizi et al. Aug 2003 B2
6605102 Mazzocchi et al. Aug 2003 B1
6610077 Hancock et al. Aug 2003 B1
6620148 Tsugita Sep 2003 B1
6620179 Brook et al. Sep 2003 B2
6620182 Khosravi et al. Sep 2003 B1
6623460 Heck Sep 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6645222 Parodi et al. Nov 2003 B1
6660013 Rabiner et al. Dec 2003 B2
6660014 Demarais et al. Dec 2003 B2
6663650 Sepetka et al. Dec 2003 B2
6692504 Kurz et al. Feb 2004 B2
6699260 Dubrul et al. Mar 2004 B2
6702830 Demarais et al. Mar 2004 B1
6719717 Johnson et al. Apr 2004 B1
6755847 Eskuri Jun 2004 B2
6767353 Shiber Jul 2004 B1
6790204 Zadno-azizi et al. Sep 2004 B2
6800080 Bates Oct 2004 B1
6818006 Douk et al. Nov 2004 B2
6824545 Sepetka et al. Nov 2004 B2
6824550 Noriega et al. Nov 2004 B1
6824553 Gene et al. Nov 2004 B1
6830561 Jansen et al. Dec 2004 B2
6846029 Ragner et al. Jan 2005 B1
6902540 Dorros et al. Jun 2005 B2
6939361 Kleshinski Sep 2005 B1
6942682 Vrba et al. Sep 2005 B2
6945977 Demarais et al. Sep 2005 B2
6960189 Bates et al. Nov 2005 B2
6960222 Vo et al. Nov 2005 B2
7004931 Hogendijk Feb 2006 B2
7004954 Voss et al. Feb 2006 B1
7036707 Aota et al. May 2006 B2
7041084 Fotjik May 2006 B2
7052500 Bashiri et al. May 2006 B2
7056328 Arnott Jun 2006 B2
7063707 Bose et al. Jun 2006 B2
7069835 Nishri et al. Jul 2006 B2
7094249 Thomas et al. Aug 2006 B1
7122034 Belhe et al. Oct 2006 B2
7128073 Van Der Burg et al. Oct 2006 B1
7152605 Khairkhahan et al. Dec 2006 B2
7179273 Palmer et al. Feb 2007 B1
7223253 Hogendijk May 2007 B2
7232432 Fulton, III et al. Jun 2007 B2
7244243 Lary Jul 2007 B2
7285126 Sepetka et al. Oct 2007 B2
7300458 Henkes et al. Nov 2007 B2
7306618 Demond et al. Dec 2007 B2
7320698 Eskuri Jan 2008 B2
7323002 Johnson et al. Jan 2008 B2
7331980 Dubrul et al. Feb 2008 B2
7481805 Magnusson Jan 2009 B2
7534234 Fotjik May 2009 B2
7578830 Kusleika et al. Aug 2009 B2
7621870 Berrada et al. Nov 2009 B2
7674247 Fotjik Mar 2010 B2
7678131 Muller Mar 2010 B2
7691121 Rosenbluth et al. Apr 2010 B2
7695458 Belley et al. Apr 2010 B2
7713282 Frazier et al. May 2010 B2
7722641 Van Der Burg et al. May 2010 B2
7763010 Evans et al. Jul 2010 B2
7766934 Pal et al. Aug 2010 B2
7775501 Kees Aug 2010 B2
7780696 Daniel et al. Aug 2010 B2
7815608 Schafersman et al. Oct 2010 B2
7905877 Oscar et al. Mar 2011 B1
7905896 Straub Mar 2011 B2
7938809 Lampropoulos et al. May 2011 B2
7938820 Webster et al. May 2011 B2
7967790 Whiting et al. Jun 2011 B2
7976511 Fotjik Jul 2011 B2
7993302 Hebert et al. Aug 2011 B2
7993363 Demond et al. Aug 2011 B2
8021351 Boldenow et al. Sep 2011 B2
8043313 Krolik et al. Oct 2011 B2
8052640 Fiorella et al. Nov 2011 B2
8057496 Fischer, Jr. Nov 2011 B2
8057497 Raju Nov 2011 B1
8066757 Ferrera et al. Nov 2011 B2
8070694 Galdonik et al. Dec 2011 B2
8070769 Broome Dec 2011 B2
8070791 Ferrera et al. Dec 2011 B2
8075510 Aklog et al. Dec 2011 B2
8080032 Van Der Burg et al. Dec 2011 B2
8088140 Ferrera et al. Jan 2012 B2
8092486 Berrada et al. Jan 2012 B2
8100935 Rosenbluth et al. Jan 2012 B2
8109962 Pal Feb 2012 B2
8118829 Carrison et al. Feb 2012 B2
8197493 Ferrera et al. Jun 2012 B2
8246641 Osborne et al. Aug 2012 B2
8261648 Marchand et al. Sep 2012 B1
8267897 Wells Sep 2012 B2
8298257 Sepetka et al. Oct 2012 B2
8317748 Fiorella et al. Nov 2012 B2
8337450 Fotjik Dec 2012 B2
RE43902 Hopkins et al. Jan 2013 E
8343167 Henson Jan 2013 B2
8357178 Grandfield et al. Jan 2013 B2
8361104 Jones et al. Jan 2013 B2
8409215 Sepetka et al. Apr 2013 B2
8480708 Kassab et al. Jul 2013 B2
8486105 Demond et al. Jul 2013 B2
8491539 Fotjik Jul 2013 B2
8512352 Martin Aug 2013 B2
8523897 Van Der Burg et al. Sep 2013 B2
8535283 Heaton et al. Sep 2013 B2
8535334 Martin Sep 2013 B2
8535343 Van Der Burg et al. Sep 2013 B2
8545526 Martin et al. Oct 2013 B2
8568432 Straub Oct 2013 B2
8568465 Freudenthal et al. Oct 2013 B2
8574262 Ferrera et al. Nov 2013 B2
8579915 French et al. Nov 2013 B2
8585713 Ferrera et al. Nov 2013 B2
8608754 Wensel et al. Dec 2013 B2
8647367 Kassab et al. Feb 2014 B2
8657867 Dorn et al. Feb 2014 B2
8696622 Fiorella et al. Apr 2014 B2
8715314 Janardhan et al. May 2014 B1
8721714 Kelley May 2014 B2
8753322 Hu et al. Jun 2014 B2
8771289 Mohiuddin et al. Jul 2014 B2
8777893 Malewicz Jul 2014 B2
8784441 Rosenbluth et al. Jul 2014 B2
8784442 Jones et al. Jul 2014 B2
8784469 Kassab Jul 2014 B2
8795305 Martin et al. Aug 2014 B2
8795345 Grandfield et al. Aug 2014 B2
8801748 Martin Aug 2014 B2
8808259 Walton et al. Aug 2014 B2
8814927 Shin et al. Aug 2014 B2
8820207 Marchand et al. Sep 2014 B2
8826791 Thompson et al. Sep 2014 B2
8828044 Aggerholm et al. Sep 2014 B2
8833224 Thompson et al. Sep 2014 B2
8834519 Van Der Burg et al. Sep 2014 B2
8845621 Fotjik Sep 2014 B2
8852226 Gilson et al. Oct 2014 B2
8939991 Krolik et al. Jan 2015 B2
8945143 Ferrera et al. Feb 2015 B2
8945172 Ferrera et al. Feb 2015 B2
8956384 Berrada et al. Feb 2015 B2
8992504 Castella et al. Mar 2015 B2
9005172 Chung Apr 2015 B2
9011551 Oral et al. Apr 2015 B2
9028401 Bacich et al. May 2015 B1
9078682 Lenker et al. Jul 2015 B2
9101382 Krolik et al. Aug 2015 B2
9125683 Farhangnia et al. Sep 2015 B2
9126016 Fulton Sep 2015 B2
9149609 Ansel et al. Oct 2015 B2
9155552 Ulm, III Oct 2015 B2
9161766 Slee et al. Oct 2015 B2
9168043 Van Der Burg et al. Oct 2015 B2
9173668 Ulm, III Nov 2015 B2
9186487 Dubrul et al. Nov 2015 B2
9204887 Cully et al. Dec 2015 B2
9216277 Myers Dec 2015 B2
9241669 Pugh et al. Jan 2016 B2
9358037 Farhangnia et al. Jan 2016 B2
9259237 Quick et al. Feb 2016 B2
9265512 Carrison et al. Feb 2016 B2
9283066 Hopkins et al. Mar 2016 B2
9301769 Brady et al. Apr 2016 B2
9351747 Kugler et al. May 2016 B2
9439664 Sos Sep 2016 B2
9439751 White et al. Sep 2016 B2
9456834 Folk Oct 2016 B2
9463035 Greenhalgh et al. Oct 2016 B1
9463036 Brady et al. Oct 2016 B2
9526864 Quick Dec 2016 B2
9526865 Quick Dec 2016 B2
9532792 Galdonik et al. Jan 2017 B2
9566073 Kassab et al. Feb 2017 B2
9566424 Pessin Feb 2017 B2
9579116 Nguyen et al. Feb 2017 B1
9581942 Shippert Feb 2017 B1
9616213 Furnish et al. Apr 2017 B2
9636206 Nguyen et al. May 2017 B2
9643035 Mastenbroek May 2017 B2
9662129 Galdonik et al. May 2017 B2
9700332 Marchand et al. Jul 2017 B2
9717488 Kassab et al. Aug 2017 B2
9717514 Martin et al. Aug 2017 B2
9717519 Rosenbluth et al. Aug 2017 B2
9744024 Nguyen et al. Aug 2017 B2
9757137 Krolik et al. Sep 2017 B2
9827084 Bonnette et al. Nov 2017 B2
9844386 Nguyen et al. Dec 2017 B2
9844387 Marchand et al. Dec 2017 B2
9848975 Hauser Dec 2017 B2
9849014 Kusleika Dec 2017 B2
9962178 Greenhalgh et al. May 2018 B2
9980813 Eller May 2018 B2
9999493 Nguyen et al. Jun 2018 B2
10004531 Rosenbluth et al. Jun 2018 B2
10010335 Greenhalgh et al. Jul 2018 B2
10016266 Hauser Jul 2018 B2
10028759 Wallace et al. Jul 2018 B2
10045790 Cox et al. Aug 2018 B2
10058339 Galdonik et al. Aug 2018 B2
10098651 Marchand et al. Oct 2018 B2
10130385 Farhangnia et al. Nov 2018 B2
10183159 Nobles et al. Jan 2019 B2
10226263 Look et al. Mar 2019 B2
10238406 Cox et al. Mar 2019 B2
10271864 Greenhalgh et al. Apr 2019 B2
10327883 Yachia Jun 2019 B2
10335186 Rosenbluth et al. Jul 2019 B2
10342571 Marchand et al. Jul 2019 B2
10349960 Quick Jul 2019 B2
10383644 Molaei et al. Aug 2019 B2
10384034 Carrison et al. Aug 2019 B2
10456555 Carrison et al. Oct 2019 B2
10478535 Ogle Nov 2019 B2
10485952 Carrison et al. Nov 2019 B2
10524811 Marchand et al. Jan 2020 B2
10531883 Deville et al. Jan 2020 B1
10588655 Rosenbluth et al. Mar 2020 B2
10695159 Hauser Jun 2020 B2
10709471 Rosenbluth et al. Jul 2020 B2
10772636 Kassab et al. Sep 2020 B2
10799331 Hauser Oct 2020 B2
10912577 Marchand et al. Feb 2021 B2
10926060 Stern et al. Feb 2021 B2
10953195 Jalgaonkar et al. Mar 2021 B2
10960114 Goisis Mar 2021 B2
11000682 Merritt et al. May 2021 B2
11013523 Arad Hadar May 2021 B2
11058445 Cox et al. Jul 2021 B2
11058451 Marchand et al. Jul 2021 B2
11065019 Chou et al. Jul 2021 B1
11147571 Cox et al. Oct 2021 B2
11154314 Quick Oct 2021 B2
11166703 Kassab et al. Nov 2021 B2
11185664 Carrison et al. Nov 2021 B2
11224450 Chou et al. Jan 2022 B2
11224721 Carrison et al. Jan 2022 B2
11259821 Buck et al. Mar 2022 B2
11305094 Carrison et al. Apr 2022 B2
11383064 Carrison et al. Jul 2022 B2
11395903 Carrison et al. Jul 2022 B2
11406801 Fojtik et al. Aug 2022 B2
11433218 Quick et al. Sep 2022 B2
11439799 Buck et al. Sep 2022 B2
11457936 Buck et al. Oct 2022 B2
11529158 Hauser Dec 2022 B2
11554005 Merritt et al. Jan 2023 B2
11559382 Merritt et al. Jan 2023 B2
11576691 Chou et al. Feb 2023 B2
11596768 Stern et al. Mar 2023 B2
11697011 Merritt et al. Jul 2023 B2
11697012 Merritt et al. Jul 2023 B2
11744691 Merritt et al. Sep 2023 B2
20010004699 Gittings et al. Jun 2001 A1
20010031981 Evans et al. Oct 2001 A1
20010041909 Tsugita et al. Nov 2001 A1
20010049486 Evans et al. Dec 2001 A1
20010051810 Dubrul et al. Dec 2001 A1
20020022858 Demond et al. Feb 2002 A1
20020022859 Hogendijk Feb 2002 A1
20020026211 Khosravi et al. Feb 2002 A1
20020032455 Boock et al. Mar 2002 A1
20020049452 Kurz et al. Apr 2002 A1
20020095161 Dhindsa Jul 2002 A1
20020095171 Belef Jul 2002 A1
20020111648 Kusleika et al. Aug 2002 A1
20020120277 Hauschild et al. Aug 2002 A1
20020147458 Hiblar et al. Oct 2002 A1
20020151918 Lafontaine et al. Oct 2002 A1
20020156457 Fisher Oct 2002 A1
20020161392 Dubrul Oct 2002 A1
20020169474 Kusleika Nov 2002 A1
20020173819 Leeflang et al. Nov 2002 A1
20020188276 Evans et al. Dec 2002 A1
20030023263 Krolik et al. Jan 2003 A1
20030083693 Daniel et al. May 2003 A1
20030100919 Hopkins et al. May 2003 A1
20030114875 Sjostrom Jun 2003 A1
20030116731 Hartley Jun 2003 A1
20030125663 Coleman et al. Jul 2003 A1
20030135151 Deng Jul 2003 A1
20030135230 Massey et al. Jul 2003 A1
20030135258 Andreas et al. Jul 2003 A1
20030153873 Luther et al. Aug 2003 A1
20030153973 Soun et al. Aug 2003 A1
20030168068 Poole et al. Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030191516 Weldon et al. Oct 2003 A1
20030208224 Broome Nov 2003 A1
20030216774 Larson Nov 2003 A1
20040019310 Hogendijk Jan 2004 A1
20040039351 Barrett Feb 2004 A1
20040039412 Isshiki et al. Feb 2004 A1
20040068288 Palmer et al. Apr 2004 A1
20040073243 Sepetka et al. Apr 2004 A1
20040098033 Leeflang et al. May 2004 A1
20040102807 Kusleika et al. May 2004 A1
20040122359 Wenz et al. Jun 2004 A1
20040127936 Salahieh et al. Jul 2004 A1
20040133232 Rosenbluth et al. Jul 2004 A1
20040138525 Saadat et al. Jul 2004 A1
20040138692 Phung et al. Jul 2004 A1
20040167567 Cano et al. Aug 2004 A1
20040199201 Kellett et al. Oct 2004 A1
20040199202 Dubrul et al. Oct 2004 A1
20040260344 Lyons et al. Dec 2004 A1
20040267272 Henniges et al. Dec 2004 A1
20050004534 Lockwood et al. Jan 2005 A1
20050033172 Dubrul et al. Feb 2005 A1
20050038468 Panetta et al. Feb 2005 A1
20050054995 Barzell et al. Mar 2005 A1
20050055047 Greenhalgh Mar 2005 A1
20050085769 MacMahon et al. Apr 2005 A1
20050085826 Nair et al. Apr 2005 A1
20050085846 Carrison et al. Apr 2005 A1
20050085849 Sepetka et al. Apr 2005 A1
20050119668 Teague et al. Jun 2005 A1
20050177132 Lentz et al. Aug 2005 A1
20050187570 Nguyen et al. Aug 2005 A1
20050203605 Dolan Sep 2005 A1
20050283165 Gadberry Dec 2005 A1
20050283166 Greenhalgh et al. Dec 2005 A1
20050283186 Berrada et al. Dec 2005 A1
20060020286 Niermann Jan 2006 A1
20060042786 West Mar 2006 A1
20060047286 West Mar 2006 A1
20060074401 Ross Apr 2006 A1
20060089533 Ziegler et al. Apr 2006 A1
20060100662 Daniel et al. May 2006 A1
20060155305 Freudenthal et al. Jul 2006 A1
20060173525 Behl et al. Aug 2006 A1
20060195137 Sepetka et al. Aug 2006 A1
20060200221 Malewicz Sep 2006 A1
20060217664 Hattler et al. Sep 2006 A1
20060224177 Finitsis Oct 2006 A1
20060229645 Bonnette et al. Oct 2006 A1
20060247500 Voegele et al. Nov 2006 A1
20060253145 Lucas Nov 2006 A1
20060264905 Eskridge et al. Nov 2006 A1
20060276874 Wilson et al. Dec 2006 A1
20060282111 Morsi Dec 2006 A1
20060293696 Fahey et al. Dec 2006 A1
20070010787 Hackett et al. Jan 2007 A1
20070038225 Osborne Feb 2007 A1
20070093744 Elmaleh Apr 2007 A1
20070112374 Paul, Jr. et al. May 2007 A1
20070118165 DeMello et al. May 2007 A1
20070149996 Coughlin Jun 2007 A1
20070161963 Smalling Jul 2007 A1
20070179513 Deutsch Aug 2007 A1
20070191866 Palmer et al. Aug 2007 A1
20070198028 Miloslavski et al. Aug 2007 A1
20070208361 Okushi et al. Sep 2007 A1
20070208367 Fiorella et al. Sep 2007 A1
20070213753 Waller Sep 2007 A1
20070213765 Adams et al. Sep 2007 A1
20070233043 Dayton et al. Oct 2007 A1
20070255252 Mehta Nov 2007 A1
20070288054 Tanaka et al. Dec 2007 A1
20080015541 Rosenbluth et al. Jan 2008 A1
20080088055 Ross Apr 2008 A1
20080157017 Macatangay et al. Jul 2008 A1
20080167678 Morsi Jul 2008 A1
20080183136 Lenker et al. Jul 2008 A1
20080228209 DeMello et al. Sep 2008 A1
20080234715 Pesce et al. Sep 2008 A1
20080234722 Bonnette et al. Sep 2008 A1
20080262528 Martin Oct 2008 A1
20080269798 Ramzipoor et al. Oct 2008 A1
20080300466 Gresham Dec 2008 A1
20080312681 Ansel et al. Dec 2008 A1
20090018566 Escudero et al. Jan 2009 A1
20090054918 Henson Feb 2009 A1
20090062841 Amplatz et al. Mar 2009 A1
20090069828 Martin et al. Mar 2009 A1
20090076417 Jones Mar 2009 A1
20090160112 Ostrovsky Jun 2009 A1
20090163846 Aklog et al. Jun 2009 A1
20090182362 Thompson et al. Jul 2009 A1
20090192495 Ostrovsky et al. Jul 2009 A1
20090281525 Harding et al. Nov 2009 A1
20090292307 Razack Nov 2009 A1
20090299393 Martin et al. Dec 2009 A1
20100016837 Howat Jan 2010 A1
20100030256 Dubrul et al. Feb 2010 A1
20100042136 Berrada et al. Feb 2010 A1
20100087844 Fischer, Jr. Apr 2010 A1
20100087850 Razack Apr 2010 A1
20100094201 Mallaby Apr 2010 A1
20100106081 Brandeis Apr 2010 A1
20100114113 Dubrul et al. May 2010 A1
20100121312 Gielenz et al. May 2010 A1
20100137846 Desai et al. Jun 2010 A1
20100190156 Van Wordragen et al. Jul 2010 A1
20100204712 Mallaby Aug 2010 A1
20100217276 Garrison et al. Aug 2010 A1
20100249815 Jantzen et al. Sep 2010 A1
20100268264 Bonnette et al. Oct 2010 A1
20100318178 Rapaport et al. Dec 2010 A1
20110034986 Chou et al. Feb 2011 A1
20110034987 Kennedy Feb 2011 A1
20110054405 Whiting et al. Mar 2011 A1
20110060212 Slee et al. Mar 2011 A1
20110071503 Takagi et al. Mar 2011 A1
20110118817 Gunderson et al. May 2011 A1
20110125181 Brady et al. May 2011 A1
20110144592 Wong et al. Jun 2011 A1
20110152823 Mohiuddin et al. Jun 2011 A1
20110152889 Ashland Jun 2011 A1
20110152993 Marchand et al. Jun 2011 A1
20110160742 Ferrera et al. Jun 2011 A1
20110160763 Ferrera et al. Jun 2011 A1
20110190806 Wittens Aug 2011 A1
20110196309 Wells Aug 2011 A1
20110196414 Porter et al. Aug 2011 A1
20110213290 Chin et al. Sep 2011 A1
20110213403 Aboytes Sep 2011 A1
20110224707 Miloslavski et al. Sep 2011 A1
20110245807 Sakata et al. Oct 2011 A1
20110251629 Galdonik et al. Oct 2011 A1
20110264133 Hanlon et al. Oct 2011 A1
20110265681 Allen et al. Nov 2011 A1
20110288529 Fulton Nov 2011 A1
20110288572 Martin Nov 2011 A1
20110319917 Ferrera et al. Dec 2011 A1
20120059309 di Palma et al. Mar 2012 A1
20120059356 di Palma et al. Mar 2012 A1
20120083824 Berrada et al. Apr 2012 A1
20120083868 Shrivastava Apr 2012 A1
20120089216 Rapaport et al. Apr 2012 A1
20120101480 Ingle et al. Apr 2012 A1
20120101510 Lenker et al. Apr 2012 A1
20120109109 Kajii May 2012 A1
20120138832 Townsend Jun 2012 A1
20120143239 Aklog et al. Jun 2012 A1
20120165919 Cox et al. Jun 2012 A1
20120172918 Fifer et al. Jul 2012 A1
20120179181 Straub et al. Jul 2012 A1
20120197277 Stinis Aug 2012 A1
20120232655 Lorrison et al. Sep 2012 A1
20120271105 Nakamura et al. Oct 2012 A1
20120271231 Agrawal Oct 2012 A1
20120277788 Cattaneo Nov 2012 A1
20120310166 Huff Dec 2012 A1
20130030460 Marks et al. Jan 2013 A1
20130035628 Garrison et al. Feb 2013 A1
20130046332 Jones et al. Feb 2013 A1
20130066348 Fiorella et al. Mar 2013 A1
20130092012 Marchand et al. Apr 2013 A1
20130096571 Massicotte et al. Apr 2013 A1
20130102996 Strauss Apr 2013 A1
20130116708 Ziniti et al. May 2013 A1
20130116721 Takagi et al. May 2013 A1
20130126559 Cowan et al. May 2013 A1
20130144326 Brady et al. Jun 2013 A1
20130150793 Beissel et al. Jun 2013 A1
20130165871 Fiorella et al. Jun 2013 A1
20130184703 Shireman et al. Jul 2013 A1
20130197454 Shibata et al. Aug 2013 A1
20130197567 Brady et al. Aug 2013 A1
20130204297 Melsheimer et al. Aug 2013 A1
20130226196 Smith Aug 2013 A1
20130281788 Garrison Oct 2013 A1
20130289608 Tanaka et al. Oct 2013 A1
20130317589 Martin et al. Nov 2013 A1
20130345739 Brady et al. Dec 2013 A1
20140005712 Martin Jan 2014 A1
20140005713 Bowman Jan 2014 A1
20140005715 Castella et al. Jan 2014 A1
20140005717 Martin et al. Jan 2014 A1
20140025048 Ward Jan 2014 A1
20140031856 Martin Jan 2014 A1
20140046133 Nakamura et al. Feb 2014 A1
20140046243 Ray et al. Feb 2014 A1
20140052161 Cully et al. Feb 2014 A1
20140074144 Shrivastava et al. Mar 2014 A1
20140121672 Folk May 2014 A1
20140155830 Bonnette et al. Jun 2014 A1
20140155980 Turjman Jun 2014 A1
20140180055 Glynn et al. Jun 2014 A1
20140180397 Gerberding et al. Jun 2014 A1
20140155908 Rosenbluth et al. Jul 2014 A1
20140188127 Dubrul et al. Jul 2014 A1
20140188143 Martin et al. Jul 2014 A1
20140222070 Belson et al. Aug 2014 A1
20140236219 Dubrul et al. Aug 2014 A1
20140243882 Ma Aug 2014 A1
20140257253 Jemison Sep 2014 A1
20140257363 Lippert Sep 2014 A1
20140276403 Follmer et al. Sep 2014 A1
20140296868 Garrison et al. Oct 2014 A1
20140303658 Bonnette et al. Oct 2014 A1
20140318354 Thompson et al. Oct 2014 A1
20140324091 Rosenbluth et al. Oct 2014 A1
20140330286 Wallace et al. Nov 2014 A1
20140336691 Jones et al. Nov 2014 A1
20140343593 Chin et al. Nov 2014 A1
20140364896 Consigny Dec 2014 A1
20140371779 Vale et al. Dec 2014 A1
20150005781 Lund-Clausen et al. Jan 2015 A1
20150005792 Ahn Jan 2015 A1
20150018859 Quick et al. Jan 2015 A1
20150018860 Quick Jan 2015 A1
20150018929 Martin et al. Jan 2015 A1
20150025555 Sos Jan 2015 A1
20150032144 Holloway Jan 2015 A1
20150059908 Mollen Mar 2015 A1
20150088190 Jensen Mar 2015 A1
20150127035 Trapp et al. May 2015 A1
20150133990 Davidson May 2015 A1
20150150672 Ma Jun 2015 A1
20150164523 Brady et al. Jun 2015 A1
20150164666 Johnson et al. Jun 2015 A1
20150173782 Garrison Jun 2015 A1
20150190155 Ulm, III Jul 2015 A1
20150190156 Ulm, III Jul 2015 A1
20150196380 Berrada et al. Jul 2015 A1
20150196744 Aboytes Jul 2015 A1
20150209058 Ferrera et al. Jul 2015 A1
20150209165 Grandfield et al. Jul 2015 A1
20150238207 Cox et al. Aug 2015 A1
20150250578 Cook et al. Sep 2015 A1
20150265299 Cooper et al. Sep 2015 A1
20150305756 Rosenbluth Oct 2015 A1
20150305859 Eller Oct 2015 A1
20150352325 Quick Dec 2015 A1
20150360001 Quick Dec 2015 A1
20150374391 Quick Dec 2015 A1
20160022293 Dubrul et al. Jan 2016 A1
20160030708 Casiello et al. Feb 2016 A1
20160038267 Allen et al. Feb 2016 A1
20160058540 Don Michael Mar 2016 A1
20160074627 Cottone Mar 2016 A1
20160106353 Schuetz et al. Apr 2016 A1
20160106448 Brady et al. Apr 2016 A1
20160106449 Brady et al. Apr 2016 A1
20160113663 Brady et al. Apr 2016 A1
20160113664 Brady et al. Apr 2016 A1
20160113665 Brady et al. Apr 2016 A1
20160113666 Quick Apr 2016 A1
20160135829 Holoehwost et al. May 2016 A1
20160143721 Rosenbluth May 2016 A1
20160151605 Welch et al. Jun 2016 A1
20160192912 Kassab et al. Jul 2016 A1
20160206344 Bruzzi et al. Jul 2016 A1
20160008014 Rosenbluth Aug 2016 A1
20160220741 Garrison et al. Aug 2016 A1
20160228134 Martin et al. Aug 2016 A1
20160262774 Honda Sep 2016 A1
20160262790 Rosenbluth et al. Sep 2016 A1
20160287276 Cox et al. Oct 2016 A1
20160367285 Sos Dec 2016 A1
20170014560 Minskoff et al. Jan 2017 A1
20170021130 Dye Jan 2017 A1
20170037548 Lee Feb 2017 A1
20170042571 Levi Feb 2017 A1
20170049942 Conlan et al. Feb 2017 A1
20170056032 Look et al. Mar 2017 A1
20170058623 Jaffrey et al. Mar 2017 A1
20170079672 Quick Mar 2017 A1
20170086864 Greenhalgh et al. Mar 2017 A1
20170100142 Look et al. Apr 2017 A1
20170105743 Vale et al. Apr 2017 A1
20170105745 Rosenbluth et al. Apr 2017 A1
20170112514 Marchand et al. Apr 2017 A1
20170143359 Nguyen et al. May 2017 A1
20170143938 Ogle et al. May 2017 A1
20170112513 Marchand et al. Jul 2017 A1
20170189041 Cox et al. Jul 2017 A1
20170196576 Long et al. Jul 2017 A1
20170233908 Kroczynski et al. Aug 2017 A1
20170252057 Bonnette et al. Sep 2017 A1
20170265878 Marchand et al. Sep 2017 A1
20170281204 Garrison et al. Oct 2017 A1
20170303939 Greenhalgh et al. Oct 2017 A1
20170303942 Greenhalgh et al. Oct 2017 A1
20170303947 Greenhalgh et al. Oct 2017 A1
20170303948 Wallace et al. Oct 2017 A1
20170319221 Chu Nov 2017 A1
20170325839 Rosenbluth et al. Nov 2017 A1
20170340867 Accisano, II Nov 2017 A1
20170348014 Wallace et al. Dec 2017 A1
20180042623 Batiste Feb 2018 A1
20180042624 Greenhalgh et al. Feb 2018 A1
20180042626 Greenhalgh et al. Feb 2018 A1
20180055999 Bare et al. Mar 2018 A1
20180064453 Garrison et al. Mar 2018 A1
20180064454 Losordo et al. Mar 2018 A1
20180070968 Wallace et al. Mar 2018 A1
20180092652 Marchand et al. Apr 2018 A1
20180104404 Ngo-Chu Apr 2018 A1
20180105963 Quick Apr 2018 A1
20180125512 Nguyen et al. May 2018 A1
20180184912 Al-Ali Jul 2018 A1
20180193043 Marchand et al. Jul 2018 A1
20180236205 Krautkremer et al. Aug 2018 A1
20180250498 Stern et al. Sep 2018 A1
20180256177 Cooper et al. Sep 2018 A1
20180256178 Cox et al. Sep 2018 A1
20180296240 Rosenbluth et al. Oct 2018 A1
20180344339 Cox et al. Dec 2018 A1
20180361116 Quick et al. Dec 2018 A1
20190000492 Casey et al. Jan 2019 A1
20190015298 Beatty et al. Jan 2019 A1
20190046219 Marchand et al. Feb 2019 A1
20190070401 Merritt et al. Mar 2019 A1
20190117244 Wallace et al. Apr 2019 A1
20190133622 Wallace et al. May 2019 A1
20190133623 Wallace et al. May 2019 A1
20190133624 Wallace et al. May 2019 A1
20190133625 Wallace et al. May 2019 A1
20190133626 Wallace et al. May 2019 A1
20190133627 Wallace et al. May 2019 A1
20190150959 Cox et al. May 2019 A1
20190231373 Quick Aug 2019 A1
20190239910 Brady et al. Aug 2019 A1
20190321071 Marchand et al. Oct 2019 A1
20190336142 Torrie et al. Nov 2019 A1
20190336148 Greenhalgh et al. Nov 2019 A1
20190365395 Tran et al. Dec 2019 A1
20190366036 Jalgaonkar et al. Dec 2019 A1
20200022711 Look et al. Jan 2020 A1
20200046368 Merritt et al. Feb 2020 A1
20200046940 Carrison et al. Feb 2020 A1
20200113412 Jensen Apr 2020 A1
20200121334 Galdonik et al. Apr 2020 A1
20210022843 Hauser Jan 2021 A1
20210038385 Popp et al. Feb 2021 A1
20210113224 Dinh Apr 2021 A1
20210137667 Sonnette et al. May 2021 A1
20210138194 Carrison et al. May 2021 A1
20210186541 Thress Jun 2021 A1
20210205577 Jalgaonkar et al. Jul 2021 A1
20210236148 Marchand et al. Aug 2021 A1
20210290925 Merritt et al. Sep 2021 A1
20210315598 Buck et al. Oct 2021 A1
20210330344 Rosenbluth et al. Oct 2021 A1
20210378694 Thress et al. Dec 2021 A1
20210393278 O'Malley et al. Dec 2021 A1
20210404464 Patoskie Dec 2021 A1
20220000505 Hauser Jan 2022 A1
20220000506 Hauser Jan 2022 A1
20220000507 Hauser Jan 2022 A1
20220015798 Marchand et al. Jan 2022 A1
20220022898 Cox et al. Jan 2022 A1
20220033888 Schnall-Levin et al. Feb 2022 A1
20220039815 Thress et al. Feb 2022 A1
20220125451 Hauser Apr 2022 A1
20220142638 Enright et al. May 2022 A1
20220151647 Dolendo et al. May 2022 A1
20220152355 Dolendo et al. May 2022 A1
20220160381 Hauser May 2022 A1
20220160382 Hauser May 2022 A1
20220160383 Hauser May 2022 A1
20220211400 Cox et al. Jul 2022 A1
20220211992 Merritt et al. Jul 2022 A1
20220240959 Quick Aug 2022 A1
20220346800 Merritt et al. Nov 2022 A1
20220346801 Merritt et al. Nov 2022 A1
20220346813 Quick Nov 2022 A1
20220347455 Merritt et al. Nov 2022 A1
20220362512 Quick et al. Nov 2022 A1
20220370761 Chou et al. Nov 2022 A1
20230046775 Quick Feb 2023 A1
20230059721 Chou et al. Feb 2023 A1
20230062809 Merritt et al. Mar 2023 A1
20230070120 Cox et al. Mar 2023 A1
20230122587 Chou et al. Apr 2023 A1
20230200970 Merritt et al. Jun 2023 A1
20230218310 Scheinblum et al. Jul 2023 A1
20230218313 Rosenbluth et al. Jul 2023 A1
20230218383 Merritt et al. Jul 2023 A1
20230233311 Merritt et al. Jul 2023 A1
20230240705 Rosenbluth et al. Aug 2023 A1
20230240706 Rosenbluth et al. Aug 2023 A1
20230241302 Merritt et al. Aug 2023 A1
20230248380 Long et al. Aug 2023 A1
20230270991 Merritt et al. Aug 2023 A1
20230310137 Merritt et al. Oct 2023 A1
20230310138 Merritt et al. Oct 2023 A1
20230310751 Merritt et al. Oct 2023 A1
Foreign Referenced Citations (105)
Number Date Country
2015210338 Aug 2015 AU
102186427 Sep 2011 CN
103764049 Apr 2014 CN
103932756 Jul 2014 CN
104068910 Oct 2014 CN
106178227 Dec 2016 CN
108348319 Jul 2018 CN
110652645 Jan 2020 CN
111281482 Jun 2020 CN
102017004383 Jul 2018 DE
1254634 Nov 2002 EP
1867290 Feb 2013 EP
2942624 Nov 2015 EP
3583972 Dec 2019 EP
3589348 Jan 2020 EP
3620204 Mar 2020 EP
3013404 Apr 2020 EP
4137070 Feb 2023 EP
1588072 Apr 1981 GB
2498349 Jul 2013 GB
H6190049 Jul 1994 JP
H07323090 Dec 1995 JP
2001522631 May 1999 JP
2004097807 Apr 2004 JP
2005-095242 Jun 2005 JP
2005230132 Sep 2005 JP
2005323702 Nov 2005 JP
2006094876 Apr 2006 JP
2011526820 Jan 2010 JP
WO1997017889 May 1997 WO
WO9833443 Aug 1998 WO
WO9838920 Sep 1998 WO
WO9839053 Sep 1998 WO
WO9851237 Nov 1998 WO
WO1999044542 Sep 1999 WO
WO0032118 Jun 2000 WO
WO2000053120 Sep 2000 WO
WO0202162 Jan 2002 WO
WO03015840 Feb 2003 WO
WO2004018916 Mar 2004 WO
WO2004093696 Nov 2004 WO
WO2005046736 May 2005 WO
WO2006029270 Mar 2006 WO
WO2006110186 Oct 2006 WO
WO2006124307 Nov 2006 WO
WO2007092820 Aug 2007 WO
WO2009082513 Jul 2009 WO
WO2009086482 Jul 2009 WO
WO2009155571 Dec 2009 WO
WO2010002549 Jan 2010 WO
WO2010010545 Jan 2010 WO
WO2010023671 Mar 2010 WO
WO2010049121 May 2010 WO
WO2010102307 Sep 2010 WO
WO2011032712 Mar 2011 WO
WO2011054531 May 2011 WO
WO2011073176 Jun 2011 WO
WO2012009675 Jan 2012 WO
WO2012011097 Jan 2012 WO
WO2012049652 Apr 2012 WO
WO2012065748 May 2012 WO
WO2012120490 Sep 2012 WO
WO2012162437 Nov 2012 WO
WO2014047650 Mar 2014 WO
WO2014081892 May 2014 WO
WO2015006782 Jan 2015 WO
WO2015061365 Apr 2015 WO
WO2015121424 Aug 2015 WO
WO2015179329 Nov 2015 WO
WO2015189354 Dec 2015 WO
WO2015191646 Dec 2015 WO
WO2016014955 Jan 2016 WO
WO2017024258 Feb 2017 WO
WO2017058280 Apr 2017 WO
WO2017070702 Apr 2017 WO
WO2017106877 Jun 2017 WO
WO2017189535 Nov 2017 WO
WO2017189550 Nov 2017 WO
WO2017189591 Nov 2017 WO
WO2017189615 Nov 2017 WO
WO2017210487 Dec 2017 WO
WO2018049317 Mar 2018 WO
WO2018065092 Apr 2018 WO
WO2018080590 May 2018 WO
WO2018148174 Aug 2018 WO
WO2019010318 Jan 2019 WO
WO2019050765 Mar 2019 WO
WO2019075444 Apr 2019 WO
WO2019094456 May 2019 WO
WO2019173475 Sep 2019 WO
WO2019222117 Nov 2019 WO
WO2019246240 Dec 2019 WO
WO2020036809 Feb 2020 WO
WO2021067134 Apr 2021 WO
WO2021076954 Apr 2021 WO
WO2021127202 Jun 2021 WO
WO2021248042 Dec 2021 WO
WO2022032173 Feb 2022 WO
WO2022103848 May 2022 WO
WO2022109021 May 2022 WO
WO2022109034 May 2022 WO
WO2023137341 Jul 2023 WO
WO2023147353 Aug 2023 WO
WO2023154612 Aug 2023 WO
WO2023192925 Oct 2023 WO
Non-Patent Literature Citations (70)
Entry
European Patent Application No. 13838945.7, Extended European Search Report, 9 pages, dated Apr. 15, 2016.
Gibbs, et al., “Temporary Stent as a bail-out device during percutaneous transluminal coronary angioplasty: preliminary clinical experience,” British Heart Journal, 1994, 71:372-377, Oct. 12, 1993, 6 pgs.
Gupta, S. et al., “Acute Pulmonary Embolism Advances in Treatment”, JAPI, Association of Physicians India, Mar. 2008, vol. 56, 185-191.
International Search Report and Written Opinion for International App. No. PCT/US13/61470, dated Jan. 17, 2014, 7 pages.
International Search Report and Written Opinion for International App. No. PCT/US2014/046567, dated Nov. 3, 2014, 13 pages.
International Search Report and Written Opinion for International App. No. PCT/US2014/061645, dated Jan. 23, 2015, 15 pages.
International Search Report for International App. No. PCT/US13/71101, dated Mar. 31, 2014, 4 pages.
Konstantinides, S. et al., “Pulmonary embolism hotline 2012—Recent and expected trials”, Thrombosis and Haemostasis, Jan. 9, 2013:33; 43-50.
Konstantinides, S. et al., “Pulmonary embolism: risk assessment and management”, European Society of Cardiology; European Heart Journal, Sep. 7, 2012:33, 3014-3022.
Kucher, N. et al., “Percutaneous Catheter Thrombectomy Device for Acute Pulmonary Embolism: In Vitro and in Vivo Testing”, Circulation, Sep. 2005:112:e28-e32.
Kucher, N., “Catheter Interventions in Massive Pulmonary Embolism”, Cardiology Rounds, Mar. 2006 vol. 10, Issue 3, 6 pages.
Kucher, N. et al., “Management of Massive Pulmonary Embolism”, Radiology, Sep. 2005:236:3852-858.
Kucher, N. et al., “Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism.” Circulation, 2014, 129, pp. 9 pages.
Kuo, W. et al., “Catheter-directed Therapy for the Treatment of Massive Pulmonary Embolism: Systematic Review and Meta-analysis of Modern Techniques”, Journal of Vascular and Interventional Radiology, Nov. 2009:20:1431-1440.
Kuo, W. et al., “Catheter-Directed Embolectomy, Fragmentation, and Thrombolysis for the Treatment of Massive Pulmonary Embolism After Failure of Systemic Thrombolysis”, American College of CHEST Physicians 2008: 134:250-254.
Kuo, W. MD, “Endovascular Therapy for Acute Pulmonary Embolism”, Continuing Medical Education Society of Interventional Radiology (“CME”); Journal of Vascular and Interventional Radiology, Feb. 2012: 23:167-179.
Lee, L. et al, “Massive pulmonary embolism: review of management strategies with a focus on catheter-based techniques”, Expert Rev. Cardiovasc. Ther. 8(6), 863-873 (2010).
Liu, S. et al, “Massive Pulmonary Embolism: Treatment with the Rotarex Thrombectomy System”, Cardiovascular Interventional Radiology; 2011: 34:106-113.
Muller-Hulsbeck, S. et al. “Mechanical Thrombectomy of Major and Massive Pulmonary Embolism with Use of the Amplatz Thrombectomy Device”, Investigative Radiology, Jun. 2001:36:6:317-322.
Reekers, J. et al., “Mechanical Thrombectomy for Early Treatment of Massive Pulmonary Embolism”, Cardiovascular and Interventional Radiology, 2003: 26:246-250.
Schmitz-Rode et al., “New Mesh Basket for Percutaneous Removal of Wall-Adherent Thrombi in Dialysis Shunts,” Cardiovasc Intervent Radiol 16:7-10 1993 4 pgs.
Schmitz-Rode et al., “Temporary Pulmonary Stent Placement as Emergency Treatment of Pulmonary Embolism,” Journal of the American College of Cardiology, vol. 48, No. 4, 2006 (5 pgs.).
Schmitz-Rode, T. et al., “Massive Pulmonary Embolism: Percutaneous Emergency Treatment by Pigtail Rotation Catheter”, JACC Journal of the American College of Cardiology, Aug. 2000:36:2:375-380.
Spiotta, A et al., “Evolution of thrombectomy approaches and devices for acute stroke: a technical review.” J NeuroIntervent Surg 2015, 7, pp. 7 pages.
Svilaas, T. et al., “Thrombus Aspiration During Primary Percutaneous Coronary Intervention.” The New England Journal of Medicine, 2008, vol. 358, No. 6, 11 pages.
Tapson, V., “Acute Pulmonary Embolism”, The New England Journal of Medicine, Mar. 6, 2008:358:2037-52.
The Penumbra Pivotal Stroke Trial Investigators, “The Penumbra Pivotal Stroke Trial: Safety and Effectiveness of a New Generation of Mechanical Devices for Clot Removal in Intracranial Large Vessel Occlusive Disease.” Stroke, 2009, 40: p. 9 pages.
Truong et al., “Mechanical Thrombectomy of lliocaval Thrombosis Using a Protective Expandable Sheath,” Cardiovasc Intervent Radiol27-254-258, 2004, 5 pgs.
Turk et al., “ADAPT FAST study: a direct aspiration first pass technique for acute stroke thrombectomy.” J NeuroIntervent Surg, vol. 6, 2014, 6 pages.
Uflacker, R., “Interventional Therapy for Pulmonary Embolism”, Journal of Vascular and Interventional Radiology, Feb. 2001: 12:147-164.
Verma, R., MD et al. “Evaluation of a Newly Developed Percutaneous Thrombectomy Basket Device in Sheep With Central Pulmonary Embolisms”, Investigative Radiology, Oct. 2006, 41, 729-734.
International Search Report and Written Opinion for International App. No. PCT/US2015/034987 filed Jun. 9, 2015, Applicant: Inceptus Medical, LLC, dated Sep. 17, 2015, 12 pages.
English translation of Japanese Office Action received for JP Application No. 2016-564210, Applicant Inceptus Medical, LLC, dated Sep. 4, 2017, 4 pages.
Australian Exam Report received for AU Application No. 2015274704, Applicant: Inceptus Medical, LLC, dated Sep. 7, 2017, 3 pages.
European Search Report received for EP Application No. 15805810.7, Applicant: Inceptus Medical, LLC, dated Sep. 4, 2017, 6 pages.
International Search Report and Written Opinion for International App. No. PCT/US2016/067628 filed Dec. 19, 2016, Applicant: Inari Medical, Inc., dated Apr. 10, 2017, 11 pages.
Goldhaber, S. et al. “Percutaneous Mechanical Thrombectomy for Acute Pulmonary Embolism—A Double-Edged Sword,” American College of CHEST Physicians, Aug. 2007, 132:2, 363-372.
Goldhaber, S., “Advanced treatment strategies for acute pulmonary embolism, including thrombolysis and embolectomy,” Journal of Thrombosis and Haemostasis, 2009: 7 (Suppl. 1): 322-327.
International Search Report and Written Opinion for International App. No. PCT/US2017/029696, Date of Filing: Apr. 26, 2017, Applicant: Inari Medical, Inc., dated Sep. 15, 2017, 19 pages.
International Search Report and Written Opinion for International App. No. PCT/US2016/058536, Date of Filing: Oct. 24, 2016, Applicant: Inari Medical, Inc., dated Mar. 13, 2017, 14 pages.
European First Office Action received for EP Application No. 13838945.7, Applicant: Inari Medical, Inc., dated Oct. 26, 2018, 7 pages.
International Search Report and Written Opinion for International App. No. PCT/US2018/048786, Date of Filing: Aug. 30, 2018, Applicant: Inari Medical, Inc., dated Dec. 13, 2018, 12 pages.
International Search Report and Written Opinion for International App. No. PCT/US2018/055780, Date of Filing: Oct. 13, 2018, Applicant: Inceptus Medical LLC., dated Jan. 22, 2019, 8 pages.
European Search Report for European Application No. 16876941.2, Date of Filing: Dec. 19, 2016, Applicant: Inari Medical, Inc., dated Jul. 18, 2019, 7 pages.
Extended European Search Report for European Application No. 16858462.1, Date of Filing: Oct. 24, 2016, Applicant: Inari Medical, Inc., dated Jun. 3, 2019, 10 pages.
International Search Report and Written Opinion for International App. No. PCT/US2019/045794, Date of Filing: Aug. 8, 2019, Applicant: Inari Medical, Inc., dated Nov. 1, 2019, 17 pages.
Partial Supplementary European Search Report for European Application No. 17864818.4, Date of Filing May 21, 2019, Applicant: Inari Medical, Inc., dated Apr. 24, 2020, 11 pages.
International Search Report and Written Opinion for International App. No. PCT/US2020/056067, Date of Filing: Oct. 16, 2020; Applicant: Inari Medical, Inc., dated Jan. 22, 2021, 8 pages.
Extended European Search Report for European Application No. 20191581.6, Applicant: Inari Medical, Inc., dated Mar. 31, 2021, 11 pages.
International Search Report and Written Opinion for International App. No. PCT/US2020/055645, Date of Filing: Dec. 17, 2020; Applicant: Inari Medical, Inc., dated Apr. 14, 2021, 12 pages.
Extended European Search Report for European Application No. 18853465.5, Applicant: Inari Medical, Inc., dated May 7, 2021, 2021, 7 pages.
Vorwerk, D. MD, et al., “Use of a Temporary Caval Filter to Assist Percutaneous Iliocaval Thrombectomy: Experimental Results.” SCVIR, 1995, 4 pages.
Wikipedia; Embolectomy; retrieved from the internet: https://en.wikipedia.org/wiki/Embolectomy; 4 pgs.; retrieved/printed: Mar. 24, 2016.
O'Sullivan; Thrombolysis versus thrombectomy in acute deep vein thrombosis; Interventional Cardiology; 3(5); pp. 589-596; Oct. 2011.
Capture Vascular Systems; (company website); retrieved from the internet: http://www.capturevascular.com; 3 pgs.; retrieved/printed: Mar. 24, 2016.
Edwards Lifesciences; Fogarty® Occlusion Catheters (product brochure); retrieved from the internet: http://web.archive.org/web/20150228193218/http://www.edwards.com/products/vascular/atraumaticocclusion/pages/occlusioncatheter.aspx; © 2011; 2 pgs.; retrieved/printed: Mar. 24, 2011.
Boston Scientific; Fetch(TM) 2 Aspiration Catheter (product information);retrieved from the internet: http://www.bostonscientific.com/en-us/products/thrombectomy-systems/fetch2-aspiration-catheter.html; 2 pgs.; retrieved/printed: Mar. 24, 2016.
Penumbra, Inc.; Indigo® System (product information); retrieved from the internet: http://www.penumbrainc.com/peripherallpercutaneous-thromboembolectomy/indigo-system; 7 pgs.; retrieved/printed: Mar. 24, 2016.
Youtube; Merci Retrieval System X Series Animation; uploaded Mar. 16, 2009 (product information); posted on May 7, 2009 by SSMDePAUL, time 1:09, retrieved from the internet: https://www.youtube.com/watch?v=MGX7deuFkhc; 3 pgs.; retrieved/printed: Mar. 24, 2016.
Covidien; Solitaire(TM) AS Neurovascular Remodeling Device (product information); retrieved from the internet: http://www.ev3.net/neuro/intl/remodeling-devices/solitaire-ab. htm; © 2015; 2 pgs. retrieved/printed: Mar. 24, 2016.
International Search Report and Written Opinion for International App. No. PCT/US21/35965, Date of Filing Jun. 4, 2021, Applicant: Inari Medical, Inc., dated Sep. 28, 2021, 12 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/45072 Date of Filing Aug. 6, 2021, Applicant: Inari Medical, Inc., dated Jan. 20, 2022, 10 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/58793; Date of Filing Nov. 10, 2021, Applicant: Inari Medical, Inc., dated Mar. 16, 2022, 13 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/59718; Date of Filing Nov. 17, 2021, Applicant: Inari Medical, Inc., dated Mar. 22, 2022, 13 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/59735; Date of Filing Nov. 17, 2021, Applicant: Inari Medical, Inc., dated Mar. 22, 2022, 11 pages.
B. Gross et al., “Dump the pump: manual aspiration thrombectomy (MAT) with a syringe is technically effective expeditious, and cost-efficient,” J NeuroIntervent Surg 2018, pp. 354-357.
Gross et al., “Dump the pump: manual aspiration thrombectomy (MAT) with a syringe is technically effective, expeditious, and cost-efficient,” J NeuroIntervent Surg, 2018, 4 pages.
International Search Report and Written Opinion for International App. No. PCT/US23/60927; filed Jan. 19, 2023, Applicant: Inari Medical, Inc., dated Jul. 20, 2023, 12 pages.
International Search Report and Written Opinion for International App. No. PCT/US23/60502; filed Jan. 11, 2023, Applicant: Inari Medical, Inc., dated May 25, 2023, 9 pages.
International Search Report and Written Opinion for International App. No. PCT/US23/61256; filed Jan. 25, 2023, Applicant: Inari Medical, Inc., dated Jun. 7, 2023, 8 pages.
Related Publications (1)
Number Date Country
20220346814 A1 Nov 2022 US
Provisional Applications (1)
Number Date Country
62622691 Jan 2018 US
Continuations (2)
Number Date Country
Parent 17498642 Oct 2021 US
Child 17865307 US
Parent 16258344 Jan 2019 US
Child 17498642 US